oxidopamine has been researched along with Parkinson Disease, Secondary in 637 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 5.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
| "Chrysin is a natural flavonoid which is found in bee propolis, honey and various plants, and neuroprotective effect of chrysin in mice was previously demonstrated by our group." | 5.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| "Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug." | 5.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
| " ALC (200mg/kg) lowered apomorphine-induced rotational asymmetry and reduced the latency to initiate and the total time in the narrow beam test, reduced striatal malondialdehyde (MDA), increased catalase activity and glutathione (GSH) level, prevented reduction of nigral tyrosine hydroxylase (TH)-positive neurons and striatal TH-immunoreactivity, and lowered striatal glial fibrillary acidic protein (GFAP) and its immunoreactivity as an indicator of astrogliosis, and nuclear factor NF-kappa B and Toll-like receptor 4 (TLR4) as reliable markers of neuroinflammation." | 3.85 | Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. ( Afshin-Majd, S; Baluchnejadmojarad, T; Bashiri, K; Kiasalari, Z; Roghani, M; Sedaghat, R, 2017) |
| " After three weeks as a recovery period, 6-OHDA-induced bradykinesia and balance disturbances were assessed by using beam traversal test 10, 30 and 60 minutes after intraperitoneal injections of the drugs (caffeine, SCH58261)." | 3.83 | Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. ( Mahmoudi, J; Reyhani-Rad, S, 2016) |
| "Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients." | 3.83 | Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. ( Eskow Jaunarajs, KL; Figge, DA; Standaert, DG, 2016) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| ") proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor." | 3.74 | Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. ( Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E, 2007) |
| " Mean firing rates were substantially higher in awake animals than in subjects anesthetized with chloral hydrate, perhaps reflecting anesthesia-induced decreases in excitatory input to striatal neurons." | 3.71 | In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions. ( Chen, MT; Hoffer, BJ; Janak, PH; Morales, M; Woodward, DJ, 2001) |
| " Because prenylated proteins are avid methyl acceptors at the terminal carboxylic acid groups, 1 micromol S-farnesylcysteine (FC) analogs blocked the SAM-induced tremors in the experimental rats." | 3.70 | Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. ( Charlton, CG; Lamango, NS, 2000) |
| "Improvements in modelling Parkinson's disease in rodents contribute to the advancement of scientific knowledge and open innumerable pathways for the development of new therapeutic interventions." | 2.48 | Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model? ( Dunnett, SB; Lelos, MJ; Lindgren, HS, 2012) |
| "Animal models of Parkinson's disease (PD) have been widely used in the past four decades to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder." | 2.48 | Animal models of Parkinson's disease. ( Armentero, MT; Blandini, F, 2012) |
| "Of these, neuroinflammation is one candidate that appears to accumulate more support with each passing year." | 2.46 | Modeling neuroinflammatory pathogenesis of Parkinson's disease. ( Barnum, CJ; Tansey, MG, 2010) |
| "Animal models have been invaluable to Parkinson's disease (PD) research." | 2.46 | Neurotoxic in vivo models of Parkinson's disease recent advances. ( Cannon, JR; Greenamyre, JT, 2010) |
| "Abnormal involuntary movements (AIMs) were scored on days 5 and 10." | 1.62 | β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease. ( Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK, 2021) |
| "Hesperidin is a flavonoid glycoside that is frequently found in citrus fruits." | 1.62 | Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis. ( Antunes, MS; Boeira, SP; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL, 2021) |
| "However, several features of Parkinson's disease (PD) have not been accounted for by this simple "classical rate model" framework, including the observation in patients with PD that movements guided by external stimuli are less impaired than otherwise identical movements generated based on internal goals." | 1.62 | Disrupted basal ganglia output during movement preparation in hemiparkinsonian mice is consistent with behavioral deficits. ( Felsen, G; Lintz, MJ; Tekriwal, A; Thompson, JA, 2021) |
| "Motor symptoms of Parkinson's disease (PD) are caused by degeneration and progressive loss of nigrostriatal dopamine neurons." | 1.56 | Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo. ( Bespalov, MM; Domanskyi, A; Karelson, M; Kopra, J; Korhonen, I; Mahato, AK; Piepponen, TP; Pulkkinen, N; Renko, JM; Ronken, E; Saarma, M; Sidorova, YA; Tuominen, RK; Visnapuu, T; Voutilainen, MH, 2020) |
| "Respiratory disturbances present in Parkinson's disease (PD) are not well understood." | 1.56 | Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease. ( Andrzejewski, K; Boguszewski, PM; Jampolska, M; Joniec-Maciejak, I; Kaczyńska, K; Zaremba, M, 2020) |
| "Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 1.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
| "Patients with Parkinson's disease (PD) manifest nonmotor and motor symptoms." | 1.56 | Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model. ( de Almeida, AG; de la Rosa, T; Gonçalves, VC; Pinheiro, DJLL; Scorza, CA; Scorza, FA, 2020) |
| " The population-based human study analyzed the data from the Taiwan Longitudinal Health Insurance Database 2005 between January 2005 and December 2013 and then used the DXM dose-response curve to investigate the trend of its protective effect against PD." | 1.51 | The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study. ( Cheng, CY; Chien, WC; Chiu, CH; Huang, YS; Kao, LT; Li, IH; Liu, CT; Ma, KH; Shih, JH; Shiue, CY, 2019) |
| "Pridopidine is a small molecule in clinical development for the treatment of Huntington's disease." | 1.51 | Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. ( Bez, F; Cenci, MA; Denis, Q; Francardo, V; Geva, M; Hayden, MR; Steiner, L, 2019) |
| "Chrysin is a natural flavonoid which is found in bee propolis, honey and various plants, and neuroprotective effect of chrysin in mice was previously demonstrated by our group." | 1.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| "In addition, the growth of implanted liver cancer was inhibited in 6-OHDA induced PD-like rats, and was associated with increased glutamate release in the serum and down-regulation of mGluR5 in tumor tissue." | 1.46 | Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer. ( An, W; Bai, XX; Bao, LH; Gu, L; Wang, XM; Xi, SS; Yang, HM; Zhang, H, 2017) |
| "Weight loss is due primarily to reduced energy intake and increased energy expenditure." | 1.46 | Brown adipose tissue activation in a rat model of Parkinson's disease. ( An, J; Fang, D; Gao, Y; Lu, T; Meng, X; Ruan, HB; Wang, L; Wang, W; Wang, X; Yang, C; Zhang, J, 2017) |
| "Sesamin is a lignan compound and the active constituent of sesame oil with antioxidant and anti-inflammatory properties." | 1.46 | Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress. ( Baluchnejadmojarad, T; Ghalami, J; Mansouri, M; Mokhtari, Z; Roghani, M, 2017) |
| "Berberine (BBR) is a renowned natural compound that exhibits potent neuroprotective activities." | 1.46 | Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways. ( Bao, J; Chen, M; Chen, S; He, C; Jia, X; Lee, SMY; Li, C; Li, P; Li, Z; Liang, Y; Liu, K; Su, H; Wan, JB; Wang, K; Wang, X; Zhang, C, 2017) |
| "This astrocytosis is similar to those observed in the parkinsonian striatum and, because it is was unaccompanied by changes in other striatal cells (e." | 1.43 | The astrocytic response to the dopaminergic denervation of the striatum. ( Morales, I; Rodriguez, M; Rodriguez-Sabate, C; Sanchez, A, 2016) |
| "Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group." | 1.42 | Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model. ( Agar, A; Aslan, M; Kaya, Y; Ogut, E; Ozsoy, O; Parlak, H; Tanriover, G; Yildirim, FB, 2015) |
| " In both rodents and nonhuman primates, we observed successful engraftment and higher dopamine levels in hpNSC-transplanted animals compared to vehicle control animals, without any adverse events." | 1.42 | Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease. ( Abramihina, T; Crain, A; Elsworth, JD; Garitaonandia, I; Gonzalez, R; Jiang, C; Laurent, LC; Morey, R; Noskov, A; Poustovoitov, M; Redmond, DE; Semechkin, R; Snyder, EY, 2015) |
| " Interestingly, chronic administration of candesartan to normal rats induced a marked increase in dopamine D1 and a decrease in dopamine D2 receptor expression." | 1.40 | Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA. ( Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B, 2014) |
| " Our results confirm that systemic 6-OHDA dosing to nonhuman primates induces cardiac sympathetic neurodegeneration and loss of catecholaminergic enzymes in the adrenal medulla, and suggests that this model can be used as a platform to evaluate disease-modifying strategies aiming to induce peripheral neuroprotection." | 1.40 | Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates. ( Dilley, K; Emborg, ME; Joers, V; Jones, C; Rahman, S; Shultz, J; Simmons, H, 2014) |
| "In Parkinson's disease, the long-term use of dopamine replacing agents is associated with the development of motor complications; therefore, there is a need for non-dopaminergic drugs." | 1.40 | Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease. ( Downey, P; Michel, A; Nicolas, JM; Scheller, D, 2014) |
| "Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug." | 1.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Curcumin pretreatment reversed these changes." | 1.38 | Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease. ( Du, XX; Jiang, H; Song, N; Wang, J; Xie, JX; Xu, HM, 2012) |
| " MRZ-8676 (6,6-dimethyl-2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one) is a novel proprietary, selective, orally bioavailable mGluR5 NAM." | 1.37 | Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. ( Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M, 2011) |
| "Parkinson's disease is a multifactorial, neurodegenerative disease where etiopathogenetic mechanisms are not fully understood." | 1.36 | Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. ( Glocker, MO; Haas, SJ; Kreutzer, M; Lessner, G; Mikkat, S; Schmitt, O; Wree, A, 2010) |
| "Depression is a frequently encountered non-motor feature of Parkinson's disease (PD) and it can have a significant impact on patient's quality of life." | 1.36 | Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. ( Andreatini, R; Barbieiro, J; Dombrowski, PA; Lima, MM; Santiago, RM; Vital, MA, 2010) |
| " Chronic administration of fenobam to previously drug-naïve animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA." | 1.36 | A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. ( Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J, 2010) |
| "Ginsenoside Rg1 has estrogen-like activities and has neuroprotective effects on the dopaminergic neurons in the 6-OHDA induced ovariectomyzed(OVX) rat model of Parkinson's disease (PD)." | 1.35 | [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease]. ( Chen, WF; Huang, WX; Liu, LX; Xie, JX; Xu, L, 2008) |
| "Dyskinesias were quantified on days 1 and 22 of levodopa treatment." | 1.35 | Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. ( Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA, 2009) |
| "Bromocriptine was encapsulated with high entrapment efficiency in all of the SLN samples, particularly in the case of tristearin/tricaprin mixture." | 1.35 | Solid lipid nanoparticles as delivery systems for bromocriptine. ( Cortesi, R; Drechsler, M; Esposito, E; Fantin, M; Lain, F; Mariani, P; Marti, M; Menegatti, E; Morari, M; Paccamiccio, L; Sivieri, E, 2008) |
| " Although levodopa improves PD symptoms in the initial stages of the disease, its long-term use is limited by the development of side effects, including abnormal involuntary movements (dyskinesias) and psychiatric complications." | 1.34 | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. ( Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG, 2007) |
| " Further microinjections of lower doses (5 and 10 nmol) revealed a dose-response effect." | 1.33 | Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. ( Ackerson, LC; Lam, HA; Maidment, NT; Phillips, JM, 2006) |
| "In the present study, a new model of Parkinson's disease is described that might help in addressing the issue of nigral cell vulnerability and to evaluate interventions with clinical potential." | 1.33 | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. ( Delville, Y; Fleming, SM; Schallert, T, 2005) |
| "Rats treated with Captopril and 6-hydroxydopamine showed significantly less reduction in the number of dopaminergic neurons (i." | 1.33 | Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. ( Labandeira-Garcia, JL; Lopez-Real, A; Mendez-Alvarez, E; Rey, P; Soto-Otero, R, 2005) |
| "Adenosine was found to be successful in up-regulating the antioxidant status, lowering the dopamine loss and functional recovery returned close to the baseline dose." | 1.32 | Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. ( Ahmad, M; Islam, F; Saleem, S; Sayeed, I; Siddiqui, A; Zafar, KS, 2003) |
| " Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally." | 1.31 | Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. ( Meltzer, LT; Schelkun, RM; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Yuen, PW, 2000) |
| " Furthermore, the inhibitory effects on striatal nerve cell firing rate by the D1 receptor agonist SKF 81297 were not different in noninnervated or reinnervated areas of the striatum compared to the control side as seen from the dose-response curves." | 1.31 | Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum. ( Andbjer, B; Fuxe, K; Kehr, J; Strömberg, I, 2000) |
| "Treatments for Parkinson's disease based on replacement of lost dopamine have several problems." | 1.31 | Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. ( Brotchie, JM; Nash, JE, 2002) |
| "In animal models of Parkinson's disease, gene transfer of aromatic L-amino acid decarboxylase (AADC) leads to an increase in the capacity of the striatum to decarboxylate exogenous L-DOPA." | 1.31 | Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. ( Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R, 2001) |
| " Since this occurred following direct administration of l-DOPA into the striatum, the decrease could not be accounted for by peripheral pharmacodynamics or bioavailability of l-DOPA in the striatum." | 1.30 | Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation. ( Brannan, T; Prikhojan, A; Yahr, MD, 1998) |
| " Peptidomimetics 3-5 each affected rotational behavior in a bell-shaped dose-response relationship producing maximal increases of 44% (1 microgram/kg,ip), 56% (0." | 1.30 | Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide. ( Gleason, WB; Johnson, RL; Khalil, EM; Mishra, RK; Ojala, WH; Pradhan, A, 1999) |
| " Chronic administration of dextromethorphan concomitant to levodopa did not prevent levodopa effect showing a significant decrease on motor response duration (124+/-4 on day 1 vs." | 1.30 | Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism. ( Bonastre, M; Jiménez, A; Marin, C; Tolosa, E, 1999) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| "Riluzole was administered twice 15 min before, and 24 h after, the lesion." | 1.29 | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. ( Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S, 1996) |
| "Apomorphine treatment increased baseline extracellular SP-LI levels up to 60% in control rats and 100% in rats with loss of nigral DA neurons." | 1.28 | Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease. ( Bennett, JP; Orosz, D, 1990) |
| "In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine." | 1.27 | Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986) |
| "To simulate an animal model of Parkinson's disease, MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) was administered to five monkeys." | 1.27 | Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. ( Imai, H; Itakura, T; Kamei, I; Komai, N; Naka, Y; Nakai, K; Nakakita, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (3.77) | 18.7374 |
| 1990's | 150 (23.55) | 18.2507 |
| 2000's | 200 (31.40) | 29.6817 |
| 2010's | 213 (33.44) | 24.3611 |
| 2020's | 50 (7.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lenda, T | 2 |
| Ossowska, K | 2 |
| Berghauzen-Maciejewska, K | 2 |
| Matłoka, M | 1 |
| Pieczykolan, J | 1 |
| Wieczorek, M | 1 |
| Konieczny, J | 2 |
| Tohge, R | 1 |
| Kaneko, S | 2 |
| Morise, S | 1 |
| Oki, M | 1 |
| Takenouchi, N | 1 |
| Murakami, A | 1 |
| Nakamura, M | 1 |
| Kusaka, H | 1 |
| Yakushiji, Y | 1 |
| Elabi, OF | 2 |
| Davies, JS | 1 |
| Lane, EL | 3 |
| Yu, H | 1 |
| Liu, X | 2 |
| Chen, B | 1 |
| Vickstrom, CR | 1 |
| Friedman, V | 1 |
| Kelly, TJ | 1 |
| Bai, X | 1 |
| Zhao, L | 1 |
| Hillard, CJ | 1 |
| Liu, QS | 1 |
| Hsieh, TH | 1 |
| He, XK | 1 |
| Liu, HH | 1 |
| Chen, JJ | 1 |
| Peng, CW | 1 |
| Liu, HL | 2 |
| Rotenberg, A | 1 |
| Chen, KT | 1 |
| Chang, MY | 1 |
| Chiang, YH | 2 |
| Chang, PK | 1 |
| Kuo, CW | 1 |
| Wang, X | 11 |
| Wang, Y | 15 |
| Chen, J | 2 |
| Li, J | 5 |
| Liu, Y | 1 |
| Chen, W | 3 |
| Parra, I | 1 |
| Martínez, I | 1 |
| Ramírez-García, G | 1 |
| Tizabi, Y | 1 |
| Mendieta, L | 1 |
| Liu, CT | 1 |
| Kao, LT | 1 |
| Shih, JH | 1 |
| Chien, WC | 1 |
| Chiu, CH | 1 |
| Ma, KH | 1 |
| Huang, YS | 1 |
| Cheng, CY | 1 |
| Shiue, CY | 1 |
| Li, IH | 1 |
| Giuliano, C | 1 |
| Siani, F | 1 |
| Mus, L | 1 |
| Ghezzi, C | 2 |
| Cerri, S | 2 |
| Pacchetti, B | 1 |
| Bigogno, C | 1 |
| Blandini, F | 5 |
| Leitner, D | 1 |
| Ramamoorthy, M | 1 |
| Dejosez, M | 1 |
| Zwaka, TP | 1 |
| Liu, W | 4 |
| Fu, R | 1 |
| Wang, Z | 2 |
| Liu, S | 2 |
| Tang, C | 1 |
| Li, L | 1 |
| Yin, D | 1 |
| Mahato, AK | 1 |
| Kopra, J | 1 |
| Renko, JM | 1 |
| Visnapuu, T | 1 |
| Korhonen, I | 1 |
| Pulkkinen, N | 1 |
| Bespalov, MM | 2 |
| Domanskyi, A | 1 |
| Ronken, E | 1 |
| Piepponen, TP | 1 |
| Voutilainen, MH | 2 |
| Tuominen, RK | 2 |
| Karelson, M | 1 |
| Sidorova, YA | 2 |
| Saarma, M | 4 |
| Jamali-Raeufy, N | 1 |
| Mojarrab, Z | 1 |
| Baluchnejadmojarad, T | 5 |
| Roghani, M | 5 |
| Fahanik-Babaei, J | 1 |
| Goudarzi, M | 1 |
| Bhattamisra, SK | 1 |
| Shak, AT | 1 |
| Xi, LW | 1 |
| Safian, NH | 1 |
| Choudhury, H | 1 |
| Lim, WM | 1 |
| Shahzad, N | 1 |
| Alhakamy, NA | 1 |
| Anwer, MK | 1 |
| Radhakrishnan, AK | 1 |
| Md, S | 1 |
| Andrzejewski, K | 1 |
| Jampolska, M | 1 |
| Zaremba, M | 1 |
| Joniec-Maciejak, I | 1 |
| Boguszewski, PM | 1 |
| Kaczyńska, K | 1 |
| Barata-Antunes, S | 1 |
| Teixeira, FG | 2 |
| Mendes-Pinheiro, B | 2 |
| Domingues, AV | 2 |
| Vilaça-Faria, H | 2 |
| Marote, A | 2 |
| Silva, D | 1 |
| Sousa, RA | 1 |
| Salgado, AJ | 2 |
| Antunes, MS | 3 |
| Cattelan Souza, L | 3 |
| Ladd, FVL | 2 |
| Ladd, AABL | 2 |
| Moreira, AL | 2 |
| Bortolotto, VC | 1 |
| Silva, MRP | 1 |
| Araújo, SM | 1 |
| Prigol, M | 1 |
| Nogueira, CW | 1 |
| Boeira, SP | 4 |
| Gonçalves, VC | 1 |
| Pinheiro, DJLL | 1 |
| de la Rosa, T | 1 |
| de Almeida, AG | 1 |
| Scorza, FA | 1 |
| Scorza, CA | 1 |
| Zhuang, W | 3 |
| Cai, M | 1 |
| Li, W | 4 |
| Chen, C | 2 |
| Lv, E | 1 |
| Fu, W | 4 |
| Goshima, Y | 1 |
| Ohshima, T | 1 |
| Kozioł, E | 1 |
| Skalicka-Woźniak, K | 1 |
| Michalak, A | 1 |
| Kaszubska, K | 1 |
| Budzyńska, B | 1 |
| Inose, Y | 1 |
| Izumi, Y | 1 |
| Takada-Takatori, Y | 1 |
| Akaike, A | 2 |
| Koyama, Y | 1 |
| Kume, T | 1 |
| Lepelletier, FX | 1 |
| Vandesquille, M | 1 |
| Asselin, MC | 1 |
| Prenant, C | 1 |
| Robinson, AC | 1 |
| Mann, DMA | 1 |
| Green, M | 1 |
| Barnett, E | 1 |
| Banister, SD | 1 |
| Mottinelli, M | 1 |
| Mesangeau, C | 1 |
| McCurdy, CR | 1 |
| Fricke, IB | 1 |
| Jacobs, AH | 2 |
| Kassiou, M | 4 |
| Boutin, H | 1 |
| Travagli, RA | 1 |
| Browning, KN | 1 |
| Camilleri, M | 1 |
| Marin, C | 5 |
| Bonastre, M | 3 |
| Fuentes, M | 2 |
| Mullol, J | 2 |
| Lian, H | 3 |
| Zhou, L | 2 |
| Zhang, Y | 4 |
| Song, YH | 1 |
| Zhang, YM | 2 |
| Cao, ZH | 1 |
| Wang, ZY | 3 |
| Abuthawabeh, R | 1 |
| Abuirmeileh, AN | 1 |
| Alzoubi, KH | 1 |
| Jalali, MS | 2 |
| Sarkaki, A | 3 |
| Farbood, Y | 2 |
| Azandeh, SS | 2 |
| Mansouri, E | 2 |
| Ghasemi Dehcheshmeh, M | 2 |
| Saki, G | 2 |
| El Nebrisi, E | 1 |
| Javed, H | 1 |
| Ojha, SK | 1 |
| Oz, M | 1 |
| Shehab, S | 1 |
| Dassati, S | 1 |
| Schweigreiter, R | 1 |
| Buechner, S | 1 |
| Waldner, A | 1 |
| Esmaeili-Mahani, S | 2 |
| Haghparast, E | 2 |
| Nezhadi, A | 1 |
| Abbasnejad, M | 2 |
| Sheibani, V | 2 |
| Dong, Y | 1 |
| Xiong, J | 1 |
| Ji, L | 1 |
| Xue, X | 1 |
| Lei, H | 3 |
| Ren, R | 2 |
| Sun, Y | 2 |
| Zhang, K | 1 |
| Zhao, X | 2 |
| Ablat, N | 2 |
| Pu, X | 2 |
| Lawler, AJ | 1 |
| Brown, AR | 1 |
| Bouchard, RS | 1 |
| Toong, N | 1 |
| Kim, Y | 2 |
| Velraj, N | 1 |
| Fox, G | 1 |
| Kleyman, M | 1 |
| Kang, B | 1 |
| Gittis, AH | 1 |
| Pfenning, AR | 1 |
| Mercado, NM | 1 |
| Stancati, JA | 1 |
| Sortwell, CE | 4 |
| Mueller, RL | 1 |
| Boezwinkle, SA | 1 |
| Duffy, MF | 1 |
| Fischer, DL | 1 |
| Sandoval, IM | 1 |
| Manfredsson, FP | 1 |
| Collier, TJ | 4 |
| Steece-Collier, K | 1 |
| Ryu, YK | 2 |
| Park, HY | 1 |
| Go, J | 1 |
| Lee, IB | 1 |
| Choi, YK | 1 |
| Lee, CH | 2 |
| Kim, KS | 3 |
| Bigham, M | 1 |
| Mohammadipour, A | 1 |
| Hosseini, M | 1 |
| Malvandi, AM | 1 |
| Ebrahimzadeh-Bideskan, A | 1 |
| Tuon, T | 1 |
| Meirelles, SS | 1 |
| de Moura, AB | 1 |
| Rosa, T | 1 |
| Borba, LA | 1 |
| Botelho, MEM | 1 |
| Abelaira, HM | 1 |
| de Mathia, GB | 1 |
| Danielski, LG | 1 |
| Fileti, ME | 1 |
| Petronilho, F | 1 |
| Ignácio, ZM | 1 |
| Quevedo, J | 1 |
| Réus, GZ | 1 |
| Cui, Q | 1 |
| Du, X | 1 |
| Chang, IYM | 1 |
| Pamukcu, A | 1 |
| Lilascharoen, V | 1 |
| Berceau, BL | 1 |
| García, D | 1 |
| Hong, D | 1 |
| Chon, U | 1 |
| Narayanan, A | 1 |
| Lim, BK | 1 |
| Chan, CS | 1 |
| Wang, WW | 1 |
| Han, R | 1 |
| He, HJ | 1 |
| Chen, SY | 1 |
| Gu, Y | 1 |
| Xie, C | 1 |
| de Luzy, IR | 1 |
| Law, KCL | 1 |
| Moriarty, N | 2 |
| Hunt, CPJ | 1 |
| Durnall, JC | 1 |
| Thompson, LH | 3 |
| Nagy, A | 1 |
| Parish, CL | 2 |
| Lages, I | 1 |
| Ribeiro, C | 1 |
| Campos, J | 1 |
| Lanceros-Mendez, S | 1 |
| Singh, A | 1 |
| Yadawa, AK | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Mishra, A | 2 |
| Singh, S | 2 |
| Lyu, Y | 1 |
| Huang, Y | 1 |
| Shi, G | 1 |
| Lei, X | 1 |
| Li, K | 1 |
| Zhou, R | 1 |
| Bai, L | 1 |
| Qin, C | 1 |
| Yan, JT | 1 |
| Liu, XY | 2 |
| Liu, JH | 2 |
| Li, GW | 1 |
| Zheng, LF | 3 |
| Zhang, XL | 2 |
| Feng, XY | 2 |
| Zhu, JX | 3 |
| Cunha, JPMCM | 1 |
| Gaceb, A | 1 |
| Fex, M | 1 |
| Paul, G | 2 |
| Tekriwal, A | 1 |
| Lintz, MJ | 1 |
| Thompson, JA | 1 |
| Felsen, G | 1 |
| Funamizu, Y | 1 |
| Nishijima, H | 1 |
| Ueno, T | 1 |
| Ueno, S | 1 |
| Mizukami, H | 1 |
| Yagihashi, S | 1 |
| Tomiyama, M | 2 |
| Alam, M | 2 |
| Rumpel, R | 1 |
| Jin, X | 1 |
| von Wrangel, C | 1 |
| Tschirner, SK | 1 |
| Krauss, JK | 1 |
| Grothe, C | 1 |
| Ratzka, A | 1 |
| Schwabe, K | 1 |
| Xi, SS | 1 |
| Bai, XX | 1 |
| Gu, L | 1 |
| Bao, LH | 1 |
| Yang, HM | 1 |
| An, W | 1 |
| Wang, XM | 4 |
| Zhang, H | 2 |
| Dong, RF | 1 |
| Zhang, B | 1 |
| Tai, LW | 1 |
| Liu, HM | 1 |
| Shi, FK | 1 |
| Liu, NN | 1 |
| Zhou, X | 1 |
| Doorduin, J | 1 |
| Elsinga, PH | 1 |
| Dierckx, RAJO | 1 |
| de Vries, EFJ | 1 |
| Casteels, C | 2 |
| Wang, L | 3 |
| Zhu, R | 1 |
| Bi, J | 1 |
| Feng, X | 1 |
| Wu, J | 2 |
| Wu, H | 1 |
| Kong, W | 1 |
| Yu, B | 1 |
| Yu, X | 1 |
| Zhai, H | 1 |
| Wang, F | 3 |
| Yin, WL | 1 |
| Yin, WG | 1 |
| Huang, BS | 1 |
| Wu, LX | 1 |
| Wang, Q | 4 |
| Li, M | 2 |
| Xie, Z | 1 |
| Cai, J | 1 |
| Li, N | 1 |
| Xiao, H | 1 |
| Wang, N | 1 |
| Wang, J | 7 |
| Luo, F | 1 |
| Zhang, W | 2 |
| Kamińska, K | 1 |
| Czarnecka, A | 1 |
| Lorenc-Koci, E | 1 |
| Wang, W | 2 |
| Meng, X | 1 |
| Yang, C | 1 |
| Fang, D | 1 |
| An, J | 1 |
| Zhang, J | 5 |
| Lu, T | 2 |
| Ruan, HB | 1 |
| Gao, Y | 2 |
| Wang, K | 3 |
| Su, WT | 1 |
| Jia, J | 3 |
| Fu, Q | 1 |
| Song, R | 1 |
| Yang, Z | 2 |
| Shan, Q | 2 |
| Goes, ATR | 1 |
| Jesse, CR | 2 |
| Lobo Ladd, FV | 2 |
| Lobo Ladd, AAB | 2 |
| Luchese, C | 1 |
| Paroul, N | 1 |
| Wang, YY | 1 |
| Jiang, HF | 1 |
| Zhao, F | 1 |
| Luo, MH | 1 |
| Luo, MM | 1 |
| Bonato, JM | 1 |
| Bassani, TB | 2 |
| Milani, H | 1 |
| Vital, MABF | 2 |
| de Oliveira, RMW | 1 |
| Qiao, D | 1 |
| Shi, K | 1 |
| Yang, X | 2 |
| Zhu, Z | 1 |
| Ding, X | 1 |
| Cui, G | 1 |
| Hua, F | 1 |
| Xiang, J | 1 |
| de Campos, PS | 1 |
| Kawamura, LRSM | 1 |
| Hasegawa, K | 1 |
| Kumei, Y | 1 |
| Zeredo, JL | 1 |
| Liu, J | 5 |
| Huang, C | 2 |
| Lin, F | 1 |
| Wang, G | 1 |
| Lu, D | 1 |
| Wu, Q | 1 |
| Shi, J | 1 |
| Zhang, F | 1 |
| Sarukhani, MR | 1 |
| Haghdoost-Yazdi, H | 4 |
| Khandan-Chelarci, G | 1 |
| Leem, E | 1 |
| Kim, HJ | 1 |
| Choi, M | 2 |
| Kim, S | 1 |
| Oh, YS | 1 |
| Lee, KJ | 1 |
| Choe, YS | 1 |
| Um, JY | 1 |
| Shin, WH | 1 |
| Jeong, JY | 1 |
| Jin, BK | 2 |
| Kim, DW | 1 |
| McLean, C | 1 |
| Fisher, PB | 1 |
| Kholodilov, N | 1 |
| Ahn, KS | 1 |
| Lee, JM | 1 |
| Jung, UJ | 1 |
| Lee, SG | 1 |
| Kim, SR | 1 |
| Wu, DM | 1 |
| Han, XR | 1 |
| Wen, X | 1 |
| Wang, S | 4 |
| Fan, SH | 1 |
| Zhuang, J | 1 |
| Wang, YJ | 1 |
| Zhang, ZF | 1 |
| Li, MQ | 1 |
| Hu, B | 1 |
| Sun, CH | 1 |
| Lu, J | 1 |
| Zheng, YL | 1 |
| de Jager, L | 1 |
| Amorim, EDT | 1 |
| Lucchetti, BFC | 1 |
| Lopes, FNC | 1 |
| Crestani, CC | 2 |
| Pinge-Filho, P | 1 |
| Martins-Pinge, MC | 2 |
| Turnes, JM | 1 |
| Souza, LC | 1 |
| Charles, KA | 1 |
| Naudet, F | 1 |
| Bouali-Benazzouz, R | 2 |
| Landry, M | 1 |
| De Deurwaerdère, P | 2 |
| Fossat, P | 1 |
| Benazzouz, A | 4 |
| Nakashima, A | 1 |
| Yamauchi, A | 1 |
| Matsumoto, J | 1 |
| Dohgu, S | 1 |
| Takata, F | 1 |
| Koga, M | 1 |
| Fukae, J | 1 |
| Tsuboi, Y | 1 |
| Kataoka, Y | 1 |
| Lv, D | 1 |
| Li, S | 1 |
| Shen, Y | 1 |
| Hu, LF | 4 |
| Liu, CF | 1 |
| Chen, HH | 1 |
| Chang, PC | 1 |
| Chan, MH | 1 |
| Bhupal, PK | 1 |
| Anderson, KA | 1 |
| Shall, GP | 1 |
| Lynn, JD | 1 |
| Hoolsema, KS | 1 |
| Rossignol, J | 1 |
| Dunbar, GL | 2 |
| Sandstrom, MI | 1 |
| Chen, S | 4 |
| Yu, SJ | 1 |
| Li, Y | 4 |
| Lecca, D | 1 |
| Glotfelty, E | 1 |
| Kim, HK | 1 |
| Choi, HI | 1 |
| Hoffer, BJ | 5 |
| Greig, NH | 1 |
| Kim, DS | 1 |
| Lai, CL | 1 |
| Lu, CC | 1 |
| Lin, HC | 1 |
| Sung, YF | 1 |
| Wu, YP | 1 |
| Hong, JS | 1 |
| Peng, GS | 1 |
| Cheng, L | 1 |
| Chen, L | 5 |
| Wei, X | 2 |
| Ren, Z | 1 |
| Zeng, S | 1 |
| Zhang, X | 2 |
| Wen, H | 1 |
| Gao, C | 1 |
| Liu, H | 2 |
| Mohanbhai, SJ | 1 |
| Tiwari, V | 1 |
| Chaturvedi, RK | 2 |
| Khurana, S | 1 |
| Shukla, S | 2 |
| Flores, AJ | 1 |
| Bartlett, MJ | 1 |
| Root, BK | 1 |
| Parent, KL | 1 |
| Heien, ML | 1 |
| Porreca, F | 1 |
| Polt, R | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Yang, G | 1 |
| Cai, Y | 2 |
| Li, R | 1 |
| Tsang, AR | 1 |
| Rajakumar, N | 1 |
| Jog, MS | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Varier, KM | 1 |
| Sumathi, T | 1 |
| Francardo, V | 2 |
| Geva, M | 1 |
| Bez, F | 1 |
| Denis, Q | 1 |
| Steiner, L | 1 |
| Hayden, MR | 1 |
| Cenci, MA | 7 |
| Oliveira, LM | 1 |
| Oliveira, MA | 1 |
| Moriya, HT | 1 |
| Moreira, TS | 1 |
| Takakura, AC | 1 |
| Magno, LAV | 1 |
| Tenza-Ferrer, H | 1 |
| Collodetti, M | 1 |
| Aguiar, MFG | 1 |
| Rodrigues, APC | 1 |
| da Silva, RS | 1 |
| Silva, JDP | 1 |
| Nicolau, NF | 1 |
| Rosa, DVF | 1 |
| Birbrair, A | 1 |
| Miranda, DM | 1 |
| Romano-Silva, MA | 1 |
| Rezaee, Z | 1 |
| Marandi, SM | 1 |
| Alaei, H | 1 |
| Esfarjani, F | 1 |
| Feyzollahzadeh, S | 1 |
| Ouchi, M | 1 |
| Kitta, T | 1 |
| Kanno, Y | 1 |
| Higuchi, M | 1 |
| Togo, M | 1 |
| Takahashi, Y | 1 |
| Moriya, K | 1 |
| Shinohara, N | 1 |
| Lee, HJ | 3 |
| Dhodary, B | 1 |
| Lee, JY | 1 |
| An, JP | 1 |
| Oh, WK | 1 |
| Lee, JC | 1 |
| Yang, JS | 1 |
| Moon, MH | 1 |
| Voronkov, DN | 1 |
| Khudoerkov, RM | 1 |
| Sal'nikova, OV | 1 |
| Stavrovskaya, AV | 1 |
| Ol'shanskii, AS | 1 |
| Gushchina, AS | 1 |
| Cucarián, JD | 1 |
| Berrío, JP | 1 |
| Rodrigues, C | 1 |
| Zancan, M | 1 |
| Wink, MR | 1 |
| de Oliveira, A | 1 |
| Del Fabbro, L | 1 |
| Rossito Goes, A | 1 |
| de Gomes, MG | 1 |
| Nunes Arantes, RV | 1 |
| Reis Simionato, A | 1 |
| Oliveira, MS | 1 |
| Furian, AF | 1 |
| Shan, C | 1 |
| Gong, YL | 1 |
| Zhuang, QQ | 1 |
| Hou, YF | 1 |
| Wang, SM | 1 |
| Zhu, Q | 1 |
| Huang, GR | 1 |
| Tao, B | 1 |
| Sun, LH | 1 |
| Zhao, HY | 1 |
| Li, ST | 1 |
| Liu, JM | 1 |
| Mariani, LL | 1 |
| Longueville, S | 1 |
| Girault, JA | 2 |
| Hervé, D | 2 |
| Gervasi, N | 1 |
| Adu, TS | 1 |
| Mabandla, MV | 1 |
| Manouchehrabadi, M | 1 |
| Farhadi, M | 1 |
| Azizi, Z | 1 |
| Torkaman-Boutorabi, A | 1 |
| Xie, L | 1 |
| Teo, XQ | 1 |
| Tiong, CX | 2 |
| Tazzari, V | 1 |
| Sparatore, A | 1 |
| Del Soldato, P | 1 |
| Dawe, GS | 2 |
| Bian, JS | 2 |
| Armentero, MT | 4 |
| Bossolasco, P | 1 |
| Cova, L | 1 |
| Healy-Stoffel, M | 1 |
| Ahmad, SO | 1 |
| Stanford, JA | 2 |
| Levant, B | 1 |
| Worlitzer, MM | 1 |
| Viel, T | 1 |
| Schwamborn, JC | 1 |
| Zheng, D | 1 |
| Jiang, X | 1 |
| Zhao, J | 1 |
| Duan, D | 1 |
| Zhao, H | 1 |
| Xu, Q | 2 |
| Ren, X | 1 |
| Zhang, T | 1 |
| Gong, X | 1 |
| Hu, G | 3 |
| Ding, W | 1 |
| Pienaar, IS | 1 |
| van de Berg, W | 1 |
| Prinz, A | 1 |
| Selesnew, LM | 1 |
| Liss, B | 1 |
| Roeper, J | 1 |
| Carlsson, T | 1 |
| Gonzalo-Gobernado, R | 3 |
| Calatrava-Ferreras, L | 1 |
| Reimers, D | 3 |
| Herranz, AS | 3 |
| Rodríguez-Serrano, M | 2 |
| Miranda, C | 1 |
| Jiménez-Escrig, A | 1 |
| Díaz-Gil, JJ | 3 |
| Bazán, E | 3 |
| Gupta, SP | 1 |
| Yadav, S | 1 |
| Singhal, NK | 1 |
| Tiwari, MN | 1 |
| Mishra, SK | 1 |
| Singh, MP | 1 |
| Plowman, EK | 1 |
| Maling, N | 1 |
| Thomas, NJ | 1 |
| Fowler, SC | 1 |
| Kleim, JA | 1 |
| Hou, Z | 1 |
| Zhang, Z | 1 |
| Meng, H | 1 |
| Lin, X | 1 |
| Sun, B | 2 |
| Fang, K | 1 |
| Fang, F | 1 |
| Liu, M | 1 |
| Heuer, A | 3 |
| Dunnett, SB | 12 |
| Lindgren, N | 1 |
| Quintino, L | 1 |
| Lundberg, C | 3 |
| Hernandez-Baltazar, D | 1 |
| Mendoza-Garrido, ME | 1 |
| Martinez-Fong, D | 2 |
| Dominguez-Meijide, A | 1 |
| Villar-Cheda, B | 1 |
| Garrido-Gil, P | 1 |
| Sierrra-Paredes, G | 1 |
| Guerra, MJ | 2 |
| Labandeira-Garcia, JL | 4 |
| Ryu, J | 1 |
| Zhang, R | 1 |
| Hong, BH | 1 |
| Yang, EJ | 1 |
| Kang, KA | 1 |
| Kim, KC | 1 |
| Noh, SJ | 1 |
| Kim, HS | 3 |
| Lee, NH | 1 |
| Hyun, JW | 1 |
| Conti, MM | 1 |
| Ostock, CY | 2 |
| Lindenbach, D | 1 |
| Goldenberg, AA | 1 |
| Kampton, E | 1 |
| Dell'isola, R | 1 |
| Katzman, AC | 1 |
| Bishop, C | 3 |
| Lobb, CJ | 1 |
| Zaheer, AK | 1 |
| Smith, Y | 1 |
| Jaeger, D | 1 |
| Liao, J | 1 |
| Xu, Y | 2 |
| Qin, B | 1 |
| Xie, J | 2 |
| Deng, C | 2 |
| Huang, X | 1 |
| Kucinski, A | 1 |
| Paolone, G | 1 |
| Bradshaw, M | 1 |
| Albin, RL | 2 |
| Sarter, M | 1 |
| Schmitz, Y | 1 |
| Castagna, C | 1 |
| Mrejeru, A | 1 |
| Lizardi-Ortiz, JE | 1 |
| Klein, Z | 1 |
| Lindsley, CW | 1 |
| Sulzer, D | 1 |
| Murphy, EM | 1 |
| Lelos, MJ | 3 |
| O'Neill, MJ | 3 |
| Chotibut, T | 1 |
| Davis, RW | 1 |
| Arnold, JC | 1 |
| Frenchek, Z | 1 |
| Gurwara, S | 1 |
| Bondada, V | 1 |
| Geddes, JW | 1 |
| Salvatore, MF | 1 |
| Kim, SN | 1 |
| Doo, AR | 1 |
| Park, JY | 1 |
| Choo, HJ | 1 |
| Shim, I | 1 |
| Park, JJ | 1 |
| Chae, Y | 1 |
| Lee, B | 1 |
| Lee, H | 2 |
| Park, HJ | 2 |
| Kwon, YW | 1 |
| Chung, YJ | 1 |
| Kim, J | 1 |
| Park, J | 1 |
| Roh, TY | 1 |
| Cho, HJ | 1 |
| Yoon, CH | 1 |
| Koo, BK | 1 |
| Tronci, E | 2 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 5 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Deltheil, T | 1 |
| Turle-Lorenzo, N | 1 |
| Liberge, M | 1 |
| Rosier, C | 1 |
| Watabe, I | 1 |
| Sreng, L | 1 |
| Amalric, M | 5 |
| Mourre, C | 1 |
| Itakura, M | 1 |
| Kohda, T | 1 |
| Kubo, T | 1 |
| Semi, Y | 1 |
| Azuma, YT | 1 |
| Nakajima, H | 1 |
| Kozaki, S | 1 |
| Takeuchi, T | 1 |
| Dieb, W | 1 |
| Ouachikh, O | 1 |
| Durif, F | 1 |
| Hafidi, A | 1 |
| Hou, J | 1 |
| Liu, Q | 1 |
| Sun, H | 1 |
| Zheng, L | 1 |
| Wang, H | 1 |
| Ba, YY | 1 |
| Wang, M | 1 |
| Guo, WW | 1 |
| Wu, X | 1 |
| Yang, H | 2 |
| Yin, X | 1 |
| Xu, H | 1 |
| Jiang, Y | 1 |
| Deng, W | 1 |
| Wu, Z | 1 |
| Xiang, H | 1 |
| Sun, P | 1 |
| Joers, V | 1 |
| Dilley, K | 1 |
| Rahman, S | 1 |
| Jones, C | 1 |
| Shultz, J | 1 |
| Simmons, H | 1 |
| Emborg, ME | 1 |
| Song, HY | 1 |
| Fan, RF | 1 |
| Nash, KR | 1 |
| Moran, P | 1 |
| Finneran, DJ | 1 |
| Hudson, C | 1 |
| Robinson, J | 1 |
| Morgan, D | 1 |
| Bickford, PC | 1 |
| Jávor-Duray, BN | 1 |
| Vinck, M | 1 |
| van der Roest, M | 1 |
| Mulder, AB | 1 |
| Stam, CJ | 1 |
| Berendse, HW | 1 |
| Voorn, P | 1 |
| Chen, X | 2 |
| Wang, T | 1 |
| Sun, YN | 1 |
| Han, LN | 1 |
| Li, LB | 1 |
| Zhang, L | 3 |
| Wu, ZH | 3 |
| Michel, A | 2 |
| Downey, P | 1 |
| Nicolas, JM | 1 |
| Scheller, D | 1 |
| Segura-Aguilar, J | 1 |
| Kostrzewa, RM | 2 |
| Issy, AC | 1 |
| Padovan-Neto, FE | 1 |
| Lazzarini, M | 1 |
| Bortolanza, M | 1 |
| Del-Bel, E | 1 |
| Silva, AS | 1 |
| Ariza, D | 1 |
| Dias, DP | 1 |
| Workman, DG | 1 |
| Tsatsanis, A | 1 |
| Lewis, FW | 1 |
| Boyle, JP | 1 |
| Mousadoust, M | 1 |
| Hettiarachchi, NT | 1 |
| Hunter, M | 1 |
| Peers, CS | 1 |
| Tétard, D | 1 |
| Duce, JA | 1 |
| Ozsoy, O | 1 |
| Yildirim, FB | 1 |
| Ogut, E | 1 |
| Kaya, Y | 1 |
| Tanriover, G | 1 |
| Parlak, H | 1 |
| Agar, A | 1 |
| Aslan, M | 1 |
| Smith, GA | 3 |
| Rocha, EM | 1 |
| Rooney, T | 1 |
| Barneoud, P | 2 |
| McLean, JR | 1 |
| Beagan, J | 1 |
| Osborn, T | 1 |
| Coimbra, M | 1 |
| Luo, Y | 1 |
| Hallett, PJ | 1 |
| Isacson, O | 2 |
| Gonzalez, R | 1 |
| Garitaonandia, I | 1 |
| Crain, A | 1 |
| Poustovoitov, M | 1 |
| Abramihina, T | 1 |
| Noskov, A | 1 |
| Jiang, C | 1 |
| Morey, R | 1 |
| Laurent, LC | 1 |
| Elsworth, JD | 2 |
| Snyder, EY | 2 |
| Redmond, DE | 1 |
| Semechkin, R | 1 |
| Stayte, S | 1 |
| Rentsch, P | 1 |
| Li, KM | 1 |
| Vissel, B | 1 |
| Santana, M | 1 |
| Palmér, T | 1 |
| Simplício, H | 1 |
| Fuentes, R | 1 |
| Petersson, P | 2 |
| Greco, R | 1 |
| Levandis, G | 3 |
| Mangione, AS | 1 |
| Fuzzati-Armentero, MT | 1 |
| Bonizzi, A | 1 |
| Avanzini, MA | 1 |
| Maccario, R | 1 |
| Naughton, C | 1 |
| Feehan, J | 1 |
| O'Toole, D | 1 |
| Dowd, E | 2 |
| Wattanathorn, J | 1 |
| Sutalangka, C | 1 |
| Peng, SP | 1 |
| Copray, S | 1 |
| Sasaki, T | 1 |
| Liu, K | 2 |
| Agari, T | 2 |
| Yasuhara, T | 2 |
| Morimoto, J | 1 |
| Okazaki, M | 1 |
| Takeuchi, H | 1 |
| Toyoshima, A | 1 |
| Sasada, S | 1 |
| Shinko, A | 1 |
| Kondo, A | 2 |
| Kameda, M | 1 |
| Miyazaki, I | 2 |
| Asanuma, M | 3 |
| Borlongan, CV | 5 |
| Nishibori, M | 1 |
| Date, I | 3 |
| Kuter, K | 1 |
| Kratochwil, M | 1 |
| Głowacka, U | 1 |
| Sugawa, MD | 1 |
| Dencher, NA | 1 |
| Labunets, IF | 1 |
| Talanov, SA | 1 |
| Vasilyev, RG | 1 |
| Rodnichenko, AE | 1 |
| Utko, NA | 1 |
| Kyzminova, IA | 1 |
| Kopjak, BS | 1 |
| Podjachenko, EV | 1 |
| Sagach, VF | 1 |
| Butenko, GM | 1 |
| Shi, C | 1 |
| Cao, J | 1 |
| Guo, Y | 1 |
| Wang, C | 1 |
| Jiang, H | 3 |
| Xu, J | 1 |
| Ma, Y | 3 |
| Qi, X | 1 |
| Ye, M | 2 |
| Han, H | 1 |
| Reyhani-Rad, S | 1 |
| Mahmoudi, J | 1 |
| Inan, SY | 1 |
| Soner, BC | 1 |
| Sahin, AS | 1 |
| Nishimura, K | 2 |
| Doi, D | 1 |
| Samata, B | 1 |
| Murayama, S | 1 |
| Tahara, T | 1 |
| Onoe, H | 1 |
| Takahashi, J | 1 |
| Kelm-Nelson, CA | 1 |
| Brauer, AF | 1 |
| Ciucci, MR | 3 |
| Zou, XD | 1 |
| Guo, SQ | 1 |
| Hu, ZW | 1 |
| Li, WL | 1 |
| Morales, I | 1 |
| Sanchez, A | 1 |
| Rodriguez-Sabate, C | 1 |
| Rodriguez, M | 3 |
| Saraiva, C | 1 |
| Paiva, J | 1 |
| Santos, T | 1 |
| Ferreira, L | 1 |
| Bernardino, L | 1 |
| Figge, DA | 1 |
| Eskow Jaunarajs, KL | 2 |
| Standaert, DG | 2 |
| Umarao, P | 1 |
| Bose, S | 1 |
| Bhattacharyya, S | 1 |
| Kumar, A | 1 |
| Jain, S | 1 |
| Suarez, LM | 1 |
| Solis, O | 1 |
| Aguado, C | 1 |
| Lujan, R | 1 |
| Moratalla, R | 2 |
| Chen, D | 1 |
| Lv, C | 1 |
| Li, F | 1 |
| Im, HJ | 1 |
| Hahm, J | 1 |
| Kang, H | 1 |
| Choi, H | 1 |
| Hwang, do W | 1 |
| Kim, EE | 1 |
| Chung, JK | 1 |
| Lee, DS | 1 |
| Dahl, R | 1 |
| Zhang, C | 2 |
| Li, C | 1 |
| Li, Z | 1 |
| Jia, X | 1 |
| Bao, J | 1 |
| Liang, Y | 1 |
| Chen, M | 1 |
| Li, P | 1 |
| Su, H | 1 |
| Wan, JB | 1 |
| Lee, SMY | 1 |
| He, C | 1 |
| Piri, H | 1 |
| Najafipour, R | 1 |
| Faraji, A | 3 |
| Fraidouni, N | 2 |
| Dargahi, T | 1 |
| Alipour Heidari, M | 1 |
| Mansouri, M | 1 |
| Ghalami, J | 1 |
| Mokhtari, Z | 1 |
| Afshin-Majd, S | 1 |
| Bashiri, K | 1 |
| Kiasalari, Z | 1 |
| Sedaghat, R | 1 |
| Westphal, R | 1 |
| Simmons, C | 1 |
| Mesquita, MB | 1 |
| Wood, TC | 1 |
| Williams, SC | 1 |
| Vernon, AC | 1 |
| Cash, D | 1 |
| Becker, G | 1 |
| Bahri, MA | 1 |
| Hustadt, F | 1 |
| Garraux, G | 1 |
| Luxen, A | 1 |
| Lemaire, C | 1 |
| Plenevaux, A | 1 |
| Bramanti, P | 1 |
| Nappi, G | 2 |
| Meng, JL | 1 |
| Ma, YY | 1 |
| Luo, HY | 1 |
| Kong, SZ | 1 |
| He, YW | 1 |
| Dong, BC | 1 |
| Wu, SH | 1 |
| He, M | 1 |
| Turner, MS | 1 |
| Gray, TS | 1 |
| Mickiewicz, AL | 1 |
| Napier, TC | 1 |
| Nadoushan, MR | 1 |
| Bagheri, M | 1 |
| Domenger, D | 1 |
| Schwarting, RK | 5 |
| Cansev, M | 1 |
| Ulus, IH | 1 |
| Maher, TJ | 1 |
| Wurtman, RJ | 2 |
| Yu, JG | 1 |
| Shen, FM | 1 |
| Cai, GJ | 1 |
| Liu, JG | 1 |
| Su, DF | 1 |
| Massie, A | 2 |
| Schallier, A | 2 |
| Mertens, B | 2 |
| Vermoesen, K | 2 |
| Bannai, S | 1 |
| Sato, H | 1 |
| Smolders, I | 1 |
| Michotte, Y | 4 |
| Sanchez, B | 1 |
| Relova, JL | 1 |
| Gallego, R | 1 |
| Ben-Batalla, I | 1 |
| Perez-Fernandez, R | 1 |
| Warraich, ST | 1 |
| Allbutt, HN | 2 |
| Billing, R | 1 |
| Radford, J | 1 |
| Coster, MJ | 2 |
| Henderson, JM | 4 |
| Henning, J | 2 |
| Strauss, U | 2 |
| Wree, A | 3 |
| Gimsa, J | 1 |
| Rolfs, A | 2 |
| Benecke, R | 2 |
| Gimsa, U | 2 |
| Yuan, CX | 1 |
| Ye, Q | 1 |
| Yuan, CG | 2 |
| Truong, L | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Santini, E | 1 |
| Alcacer, C | 1 |
| Cacciatore, S | 1 |
| Heiman, M | 1 |
| Greengard, P | 2 |
| Valjent, E | 1 |
| Fisone, G | 1 |
| Osuna, C | 1 |
| Asensio, MJ | 2 |
| Baena, S | 1 |
| Xue, Y | 1 |
| Bai, B | 1 |
| Yung, WH | 1 |
| Anastasía, A | 1 |
| Torre, L | 1 |
| de Erausquin, GA | 1 |
| Mascó, DH | 1 |
| Shimohama, S | 3 |
| Bustos, G | 1 |
| Abarca, J | 1 |
| Bustos, V | 1 |
| Riquelme, E | 1 |
| Noriega, V | 1 |
| Moya, C | 1 |
| Campusano, J | 1 |
| Fei, XF | 2 |
| Qin, ZH | 1 |
| Xiang, B | 1 |
| Li, LY | 2 |
| Han, F | 1 |
| Fukunaga, K | 1 |
| Liang, ZQ | 2 |
| Song, L | 1 |
| Kong, M | 2 |
| Ba, M | 2 |
| Liu, Z | 2 |
| Zhang, QJ | 2 |
| Ali, U | 2 |
| Gui, ZH | 2 |
| Kalda, A | 1 |
| Herm, L | 1 |
| Rinken, A | 1 |
| Zharkovsky, A | 1 |
| Chen, JF | 5 |
| Nikkhah, G | 6 |
| Rosenthal, C | 3 |
| Falkenstein, G | 3 |
| Roedter, A | 1 |
| Papazoglou, A | 1 |
| Brandis, A | 1 |
| Cuomo, D | 1 |
| Martella, G | 1 |
| Barabino, E | 1 |
| Platania, P | 1 |
| Vita, D | 1 |
| Madeo, G | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Oueslati, N | 1 |
| Pin, JP | 1 |
| Acher, F | 1 |
| Pisani, A | 1 |
| Beurrier, C | 1 |
| Melon, C | 2 |
| Kerkerian-Le Goff, L | 3 |
| Gubellini, P | 1 |
| Marinova-Mutafchieva, L | 1 |
| Sadeghian, M | 1 |
| Broom, L | 1 |
| Davis, JB | 1 |
| Medhurst, AD | 1 |
| Dexter, DT | 2 |
| Qu, L | 1 |
| Vlamings, R | 1 |
| Visser-Vandewalle, V | 1 |
| Kozan, R | 1 |
| Kaplan, S | 1 |
| Steinbusch, HW | 2 |
| Temel, Y | 1 |
| Zhu, Qf | 1 |
| Ma, J | 2 |
| Yu, Ll | 1 |
| Piltonen, M | 1 |
| Ervasti, D | 1 |
| Matilainen, T | 1 |
| Rauvala, H | 1 |
| Männistö, PT | 1 |
| Lehtonen, E | 1 |
| Vercammen, L | 1 |
| Bockstael, O | 1 |
| Chtarto, A | 1 |
| Levivier, M | 1 |
| Brotchi, J | 1 |
| Baekelandt, V | 2 |
| Sarre, S | 2 |
| Tenenbaum, L | 1 |
| Bäck, S | 1 |
| Pörsti, E | 1 |
| Toppinen, L | 1 |
| Lindgren, L | 1 |
| Lindholm, P | 2 |
| Peränen, J | 2 |
| Grealish, S | 1 |
| Kirik, D | 8 |
| Björklund, A | 14 |
| Xu, L | 2 |
| Chen, WF | 2 |
| Wong, MS | 1 |
| Aguilar, E | 1 |
| Mengod, G | 2 |
| Cortés, R | 2 |
| Obeso, JA | 1 |
| Huang, XF | 1 |
| Meyer, B | 1 |
| Wu, A | 1 |
| Yu, Y | 1 |
| Ying, W | 1 |
| Yang, GY | 1 |
| Yenari, MA | 1 |
| Hui, YP | 1 |
| Li, Q | 3 |
| Tajiri, N | 1 |
| Shingo, T | 1 |
| Yuan, W | 1 |
| Kadota, T | 1 |
| Baba, T | 1 |
| Tayra, JT | 1 |
| Morimoto, T | 1 |
| Jing, M | 1 |
| Kikuchi, Y | 1 |
| Kuramoto, S | 2 |
| Miyoshi, Y | 1 |
| Fujino, H | 1 |
| Obata, F | 1 |
| Takeda, I | 1 |
| Furuta, T | 1 |
| Greco, B | 1 |
| Lopez, S | 2 |
| van der Putten, H | 1 |
| Flor, PJ | 1 |
| Lu, M | 1 |
| da Conceição, FS | 1 |
| Ngo-Abdalla, S | 1 |
| Houzel, JC | 1 |
| Rehen, SK | 1 |
| Zigmond, MJ | 7 |
| Cameron, JL | 1 |
| Leak, RK | 1 |
| Mirnics, K | 1 |
| Russell, VA | 2 |
| Smeyne, RJ | 1 |
| Smith, AD | 3 |
| Navailles, S | 2 |
| Bioulac, B | 1 |
| Gross, C | 1 |
| Choi, HS | 1 |
| Park, MS | 1 |
| Kim, SH | 1 |
| Hwang, BY | 1 |
| Lee, CK | 1 |
| Lee, MK | 1 |
| Carta, AR | 1 |
| Frau, L | 2 |
| Pinna, A | 1 |
| Rylander, D | 1 |
| Iderberg, H | 1 |
| Dekundy, A | 2 |
| Li, H | 1 |
| Baishen, R | 1 |
| Danysz, W | 2 |
| Bezard, E | 1 |
| Santiago, RM | 1 |
| Barbieiro, J | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Andreatini, R | 1 |
| Vital, MA | 1 |
| Hosseini, SS | 1 |
| Nahid, D | 1 |
| Jahanihashemi, H | 1 |
| Goursaud, S | 1 |
| Meshul, CK | 2 |
| Hermans, E | 1 |
| Zheng, Z | 2 |
| Sun, X | 1 |
| Lu, E | 1 |
| Yang, L | 1 |
| Lu, C | 1 |
| Matsui, H | 1 |
| Ito, H | 1 |
| Taniguchi, Y | 1 |
| Inoue, H | 1 |
| Takeda, S | 1 |
| Takahashi, R | 1 |
| Jouve, L | 1 |
| Salin, P | 2 |
| Lessner, G | 1 |
| Schmitt, O | 1 |
| Haas, SJ | 2 |
| Mikkat, S | 1 |
| Kreutzer, M | 1 |
| Glocker, MO | 1 |
| Vandeputte, C | 1 |
| Taymans, JM | 1 |
| Coun, F | 1 |
| Ni, Y | 1 |
| Van Laere, K | 1 |
| Morris, JK | 1 |
| Bomhoff, GL | 1 |
| Geiger, PC | 1 |
| Gonzalez-Aparicio, R | 1 |
| Flores, JA | 2 |
| Fernandez-Espejo, E | 1 |
| Tobón-Velasco, JC | 1 |
| Carmona-Aparicio, L | 1 |
| Ali, SF | 1 |
| Santamaría, A | 1 |
| Cannon, JR | 2 |
| Greenamyre, JT | 2 |
| Lelos, M | 1 |
| Barnum, CJ | 1 |
| Tansey, MG | 1 |
| Hellman, M | 1 |
| Arumäe, U | 1 |
| Yu, LY | 1 |
| Permi, P | 1 |
| Liu, LX | 1 |
| Xie, JX | 2 |
| Huang, WX | 1 |
| Klusa, VZ | 1 |
| Isajevs, S | 2 |
| Svirina, D | 1 |
| Pupure, J | 1 |
| Beitnere, U | 2 |
| Rumaks, J | 1 |
| Svirskis, S | 1 |
| Jansone, B | 2 |
| Dzirkale, Z | 1 |
| Muceniece, R | 1 |
| Kalvinsh, I | 2 |
| Vinters, HV | 1 |
| Gao, DM | 2 |
| Zhang, JG | 1 |
| Liu, HG | 1 |
| Gravius, A | 1 |
| Hechenberger, M | 1 |
| Pietraszek, M | 1 |
| Nagel, J | 1 |
| Tober, C | 1 |
| van der Elst, M | 1 |
| Mela, F | 1 |
| Parsons, CG | 1 |
| Xia, LP | 1 |
| Finberg, JP | 2 |
| Gluzman, Z | 1 |
| Reshef, M | 1 |
| Loboda, Y | 1 |
| Mohsen, U | 1 |
| Bressler-Stramer, T | 1 |
| Miari, R | 1 |
| Gepstein, L | 1 |
| Marom, S | 1 |
| Feld, Y | 1 |
| Nandhu, MS | 2 |
| Paul, J | 2 |
| Kuruvilla, KP | 1 |
| Malat, A | 1 |
| Romeo, C | 1 |
| Paulose, CS | 2 |
| Dupre, KB | 1 |
| Button, T | 1 |
| Savage, LM | 1 |
| Wolf, W | 1 |
| Kuruvila, KP | 1 |
| Abraham, PM | 1 |
| Antony, S | 1 |
| Russell, JA | 1 |
| Schaser, AJ | 1 |
| Doll, EJ | 1 |
| Vinney, LM | 1 |
| Connor, NP | 1 |
| Sun, W | 1 |
| Sugiyama, K | 1 |
| Asakawa, T | 1 |
| Yamaguchi, H | 1 |
| Akamine, S | 1 |
| Ouchi, Y | 1 |
| Magata, Y | 1 |
| Namba, H | 1 |
| Movahedi, M | 1 |
| Hadibeygi, E | 1 |
| Vaezi, F | 1 |
| Chung, S | 1 |
| Moon, JI | 1 |
| Leung, A | 1 |
| Aldrich, D | 1 |
| Lukianov, S | 1 |
| Kitayama, Y | 1 |
| Park, S | 1 |
| Bolshakov, VY | 1 |
| Lamonerie, T | 1 |
| Howard, CD | 1 |
| Keefe, KA | 1 |
| Garris, PA | 1 |
| Daberkow, DP | 1 |
| Casas, S | 1 |
| García, S | 1 |
| Cabrera, R | 1 |
| Nanfaro, F | 1 |
| Escudero, C | 1 |
| Yunes, R | 1 |
| Kita, H | 1 |
| Kita, T | 1 |
| Kabuto, H | 2 |
| Yamanushi, TT | 1 |
| Latchoumycandane, C | 1 |
| Anantharam, V | 1 |
| Jin, H | 1 |
| Kanthasamy, A | 2 |
| Du, J | 1 |
| Sun, ZL | 1 |
| Lin, YH | 1 |
| Cheng, JH | 1 |
| Yu, JW | 1 |
| Gilmour, TP | 1 |
| Piallat, B | 1 |
| Lieu, CA | 1 |
| Venkiteswaran, K | 1 |
| Ramachandra, R | 1 |
| Rao, AN | 1 |
| Petticoffer, AC | 1 |
| Berk, MA | 1 |
| Subramanian, T | 1 |
| Li, XF | 1 |
| Song, J | 1 |
| Hong, F | 1 |
| Tang, YY | 1 |
| Yin, LL | 1 |
| Geng, XC | 1 |
| Zhu, XZ | 1 |
| Chagniel, L | 1 |
| Robitaille, C | 1 |
| Lebel, M | 1 |
| Cyr, M | 1 |
| Bové, J | 3 |
| Perier, C | 3 |
| Delaville, C | 1 |
| Chao, OY | 1 |
| Pum, ME | 1 |
| Li, JS | 1 |
| Huston, JP | 6 |
| Isajeva, D | 1 |
| Klusa, V | 1 |
| Martinez, A | 1 |
| Macheda, T | 1 |
| Morgese, MG | 2 |
| Trabace, L | 1 |
| Giuffrida, A | 2 |
| Yamawaki, N | 1 |
| Magill, PJ | 1 |
| Woodhall, GL | 1 |
| Hall, SD | 1 |
| Stanford, IM | 1 |
| Tieu, K | 1 |
| Lerner, TN | 1 |
| Kreitzer, AC | 1 |
| Choe, MA | 1 |
| An, GJ | 1 |
| Koo, BS | 1 |
| Jeon, S | 1 |
| Mercanti, G | 1 |
| Bazzu, G | 1 |
| Giusti, P | 2 |
| Tanaka, K | 1 |
| Fukuoka, S | 1 |
| Kawahara, S | 1 |
| Kimoto, N | 1 |
| Ogawa, N | 2 |
| Jang, DP | 1 |
| Min, HK | 1 |
| Lee, SY | 1 |
| Kim, IY | 1 |
| Park, HW | 1 |
| Im, YH | 1 |
| Lee, S | 1 |
| Sim, J | 1 |
| Kim, YB | 1 |
| Paek, SH | 1 |
| Cho, ZH | 1 |
| Fleming, SM | 2 |
| Schallert, T | 8 |
| Decressac, M | 1 |
| Mattsson, B | 1 |
| Ohlin, KE | 1 |
| Sebastianutto, I | 1 |
| Adkins, CE | 1 |
| Lundblad, C | 1 |
| Lockman, PR | 1 |
| Carbone, M | 1 |
| Duty, S | 3 |
| Rattray, M | 1 |
| Thornton, E | 1 |
| Vink, R | 1 |
| Soto-Otero, R | 2 |
| Méndez-Álvarez, E | 2 |
| Sánchez-Iglesias, S | 1 |
| Rodríguez-Pallares, J | 1 |
| Zubkov, FI | 1 |
| Zaytsev, VP | 1 |
| Voskressensky, LG | 1 |
| Varlamov, AV | 1 |
| de Candia, M | 1 |
| Fiorella, F | 1 |
| Altomare, C | 1 |
| Ramos-Moreno, T | 1 |
| Castillo, CG | 1 |
| Martínez-Serrano, A | 2 |
| Du, XX | 1 |
| Xu, HM | 1 |
| Song, N | 1 |
| Dimatelis, JJ | 1 |
| Hendricks, S | 1 |
| Hsieh, J | 1 |
| Vlok, NM | 1 |
| Bugarith, K | 1 |
| Daniels, WM | 1 |
| Lindgren, HS | 1 |
| Yuste, JE | 1 |
| Echeverry, MB | 1 |
| Ros-Bernal, F | 1 |
| Gomez, A | 1 |
| Ros, CM | 1 |
| Campuzano, CM | 1 |
| Fernandez-Villalba, E | 1 |
| Herrero, MT | 1 |
| Rampersaud, N | 1 |
| Harkavyi, A | 1 |
| Giordano, G | 1 |
| Lever, R | 2 |
| Whitton, J | 1 |
| Whitton, PS | 2 |
| Sleeman, IJ | 1 |
| Boshoff, EL | 1 |
| Sutton, AC | 2 |
| Yu, W | 2 |
| Calos, ME | 2 |
| Smith, AB | 1 |
| Ramirez-Zamora, A | 1 |
| Molho, ES | 2 |
| Pilitsis, JG | 1 |
| Brotchie, JM | 9 |
| Shin, DS | 2 |
| Ueda, Y | 1 |
| Tokashiki, S | 1 |
| Kanemaru, A | 1 |
| Kojima, T | 1 |
| Mueller, LE | 1 |
| Berk, M | 1 |
| Shim, J | 1 |
| Carlen, PL | 1 |
| McConnell, GC | 1 |
| So, RQ | 1 |
| Hilliard, JD | 1 |
| Lopomo, P | 1 |
| Grill, WM | 1 |
| Halje, P | 1 |
| Tamtè, M | 1 |
| Richter, U | 1 |
| Mohammed, M | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Morin, N | 1 |
| Jourdain, VA | 1 |
| Di Paolo, T | 1 |
| Heim, C | 1 |
| Sova, L | 1 |
| Kurz, T | 1 |
| Kolasiewicz, W | 1 |
| Schwegler, H | 1 |
| Sontag, KH | 1 |
| Nash, JE | 3 |
| Murray, TK | 2 |
| Messenger, MJ | 1 |
| Ward, MA | 2 |
| Woodhouse, S | 2 |
| Osborne, DJ | 2 |
| Jacoby, DB | 1 |
| Lindberg, C | 1 |
| Ratliff, J | 1 |
| Wetzel, K | 1 |
| Stewart, GR | 1 |
| Dinsmore, J | 1 |
| Behzadi, G | 1 |
| Oiwa, Y | 2 |
| Yoshimura, R | 1 |
| Nakai, K | 2 |
| Itakura, T | 3 |
| Klintenberg, R | 1 |
| Svenningsson, P | 2 |
| Gunne, L | 2 |
| Andrén, PE | 3 |
| Nichols, NF | 1 |
| Cimini, MG | 1 |
| Haas, JV | 1 |
| Staton, BA | 1 |
| Tedroff, J | 2 |
| Svensson, KA | 1 |
| Scherfler, C | 1 |
| Donnemiller, E | 1 |
| Schocke, M | 1 |
| Dierkes, K | 1 |
| Decristoforo, C | 1 |
| Oberladstätter, M | 1 |
| Kolbitsch, C | 1 |
| Zschiegner, F | 1 |
| Riccabona, G | 1 |
| Poewe, W | 1 |
| Wenning, G | 1 |
| Sanchez-Pernaute, R | 2 |
| Harvey-White, J | 3 |
| Bankiewicz, KS | 7 |
| Holtz, WA | 1 |
| O'Malley, KL | 2 |
| Petzer, JP | 2 |
| Steyn, S | 1 |
| Castagnoli, KP | 1 |
| Schwarzschild, MA | 4 |
| Van der Schyf, CJ | 1 |
| Castagnoli, N | 2 |
| Lim, S | 1 |
| Joo, WS | 1 |
| Yin, CS | 1 |
| Lee, HS | 1 |
| Seo, JC | 1 |
| Leem, K | 1 |
| Son, YS | 1 |
| Kim, YJ | 1 |
| Kim, CJ | 2 |
| Kim, YS | 1 |
| Chung, JH | 1 |
| Sun, S | 1 |
| Cao, X | 1 |
| Tong, E | 1 |
| Cohen, AD | 2 |
| Tillerson, JL | 3 |
| Sun, M | 1 |
| Zhang, GR | 1 |
| Kong, L | 1 |
| Holmes, C | 1 |
| Goldstein, DS | 1 |
| Geller, AI | 1 |
| Armstrong, RJ | 2 |
| Tyers, P | 3 |
| Jain, M | 1 |
| Richards, A | 3 |
| Rosser, AE | 3 |
| Barker, RA | 4 |
| Gilgun-Sherki, Y | 1 |
| Melamed, E | 2 |
| Ziv, I | 1 |
| Offen, D | 1 |
| Lai, SK | 1 |
| Tse, YC | 1 |
| Yang, MS | 1 |
| Wong, CK | 1 |
| Chan, YS | 1 |
| Yung, KK | 1 |
| Parati, EA | 1 |
| Bez, A | 1 |
| Ponti, D | 1 |
| Sala, S | 1 |
| Pozzi, S | 1 |
| Pagano, SF | 1 |
| Chang, CF | 1 |
| Morales, M | 2 |
| Harvey, BK | 1 |
| Su, TP | 1 |
| Tsao, LI | 1 |
| Thiemermann, C | 1 |
| Hui, GZ | 1 |
| Guo, LH | 1 |
| Reiser, J | 1 |
| Zafar, KS | 1 |
| Siddiqui, A | 1 |
| Sayeed, I | 1 |
| Ahmad, M | 4 |
| Saleem, S | 3 |
| Islam, F | 4 |
| Bibbiani, F | 2 |
| Oh, JD | 4 |
| Chase, TN | 6 |
| Whalley, K | 1 |
| Hicks, CA | 1 |
| Skolnick, P | 1 |
| Jollivet, C | 1 |
| Aubert-Pouessel, A | 1 |
| Clavreul, A | 1 |
| Venier-Julienne, MC | 1 |
| Montero-Menei, CN | 1 |
| Benoit, JP | 1 |
| Menei, P | 1 |
| Coccurello, R | 1 |
| Breysse, N | 2 |
| Xu, B | 1 |
| Jiang, CC | 1 |
| Li, BM | 1 |
| Chen, ZP | 1 |
| Guan, YH | 1 |
| Liu, XD | 1 |
| Zhang, FL | 1 |
| Kimura, T | 1 |
| Maeda, T | 1 |
| Tanaka, H | 1 |
| Kannari, K | 1 |
| Baba, M | 1 |
| Paillé, V | 1 |
| Brachet, P | 1 |
| Damier, P | 1 |
| Wessell, RH | 1 |
| Ahmed, SM | 1 |
| Menniti, FS | 1 |
| Puskovic, V | 1 |
| Wolfe, D | 1 |
| Goss, J | 1 |
| Huang, S | 1 |
| Mata, M | 1 |
| Glorioso, JC | 1 |
| Fink, DJ | 1 |
| Delville, Y | 1 |
| Eslamboli, A | 1 |
| Georgievska, B | 4 |
| Ridley, RM | 1 |
| Baker, HF | 1 |
| Muzyczka, N | 1 |
| Burger, C | 1 |
| Mandel, RJ | 5 |
| Annett, L | 1 |
| Richardson, RM | 1 |
| Broaddus, WC | 1 |
| Holloway, KL | 1 |
| Fillmore, HL | 1 |
| Johnston, TH | 1 |
| Collingridge, GL | 1 |
| Garner, CC | 1 |
| Yang, Y | 1 |
| Ding, JH | 1 |
| Stanic, D | 1 |
| Tomas, D | 1 |
| Patch, J | 1 |
| Horne, MK | 1 |
| Bourke, D | 1 |
| Finkelstein, DI | 1 |
| Fjord-Larsen, L | 1 |
| Johansen, JL | 1 |
| Kusk, P | 1 |
| Tornøe, J | 1 |
| Grønborg, M | 1 |
| Rosenblad, C | 6 |
| Wahlberg, LU | 1 |
| Serrats, J | 1 |
| Tolosa, E | 2 |
| Ahmad, AS | 3 |
| Ansari, MA | 2 |
| Yousuf, S | 3 |
| Hoda, MN | 3 |
| Lopez-Real, A | 1 |
| Rey, P | 1 |
| Taylor, JL | 1 |
| Walker, PD | 3 |
| Sanftner, LM | 1 |
| Rivera, VM | 1 |
| Suzuki, BM | 1 |
| Feng, L | 1 |
| Berk, L | 1 |
| Zhou, S | 1 |
| Forsayeth, JR | 1 |
| Clackson, T | 1 |
| Cunningham, J | 2 |
| Inden, M | 1 |
| Kitamura, Y | 1 |
| Kondo, J | 1 |
| Hayashi, K | 1 |
| Yanagida, T | 1 |
| Takata, K | 1 |
| Tsuchiya, D | 1 |
| Yanagisawa, D | 1 |
| Taniguchi, T | 1 |
| Sugimoto, H | 1 |
| Yu, L | 1 |
| Oueslati, A | 1 |
| Ericson, C | 1 |
| Lobo, MV | 1 |
| Paíno, CL | 1 |
| Alonso, R | 1 |
| Fiorentini, C | 1 |
| Rizzetti, MC | 1 |
| Busi, C | 1 |
| Bontempi, S | 1 |
| Collo, G | 1 |
| Spano, P | 1 |
| Missale, C | 1 |
| Kanaan, NM | 1 |
| Marchionini, DM | 1 |
| McGuire, SO | 1 |
| Fleming, MF | 1 |
| Sharma, R | 1 |
| McMillan, CR | 1 |
| Tenn, CC | 1 |
| Niles, LP | 1 |
| Prou, D | 1 |
| Przedborski, S | 1 |
| Phillips, JM | 1 |
| Lam, HA | 1 |
| Ackerson, LC | 1 |
| Maidment, NT | 2 |
| Seth, K | 1 |
| Agrawal, AK | 2 |
| Khan, MB | 2 |
| Ishrat, T | 1 |
| Napolitano, M | 1 |
| Picconi, B | 1 |
| Centonze, D | 1 |
| Bernardi, G | 2 |
| Calabresi, P | 2 |
| Gulino, A | 1 |
| Wu, SP | 1 |
| Fu, AL | 1 |
| Wang, YX | 1 |
| Yu, LP | 1 |
| Jia, PY | 1 |
| Jin, GZ | 1 |
| Sun, MJ | 1 |
| Brundin, P | 4 |
| Angela Cenci, M | 1 |
| Wieloch, T | 1 |
| Keep, RF | 1 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Xi, G | 1 |
| Gonzalez-Barrios, JA | 1 |
| Lindahl, M | 1 |
| Bannon, MJ | 1 |
| Anaya-Martínez, V | 1 |
| Flores, G | 1 |
| Navarro-Quiroga, I | 1 |
| Trudeau, LE | 1 |
| Aceves, J | 1 |
| Martinez-Arguelles, DB | 1 |
| Garcia-Villegas, R | 1 |
| Jiménez, I | 1 |
| Segovia, J | 3 |
| Schmidt, WJ | 1 |
| Kostrzewa, JP | 1 |
| Brus, R | 1 |
| Kostrzewa, RA | 1 |
| Nowak, P | 1 |
| Breit, S | 2 |
| Lessmann, L | 1 |
| Unterbrink, D | 1 |
| Popa, RC | 2 |
| Gasser, T | 2 |
| Schulz, JB | 2 |
| Ma, G | 1 |
| Lu, G | 1 |
| Smith, CP | 1 |
| Collins, MA | 1 |
| Avila, I | 1 |
| Christophersen, NS | 1 |
| Raymon, H | 1 |
| Kiaer, C | 1 |
| Smith, R | 1 |
| Bazzini, E | 1 |
| Wang, XJ | 1 |
| Zhang, YH | 1 |
| Lu, GQ | 1 |
| Liang, L | 2 |
| Xu, JY | 1 |
| Chen, SD | 3 |
| Xue, YQ | 1 |
| Zhao, LR | 1 |
| Guo, WP | 1 |
| Duan, WM | 2 |
| Benabid, AL | 1 |
| Simola, N | 1 |
| Borsini, F | 1 |
| Schintu, N | 1 |
| Carminati, P | 1 |
| Sun, J | 1 |
| Gao, Q | 1 |
| Miller, K | 1 |
| Bao, L | 1 |
| Poon, WS | 1 |
| Chen, XY | 1 |
| Qi, WQ | 1 |
| Shen, SH | 1 |
| De Leonibus, E | 1 |
| Pascucci, T | 1 |
| Oliverio, A | 1 |
| Mele, A | 1 |
| Yoon, MC | 1 |
| Shin, MS | 1 |
| Kim, TS | 1 |
| Kim, BK | 1 |
| Ko, IG | 1 |
| Sung, YH | 1 |
| Kim, SE | 1 |
| Lee, HH | 1 |
| Kim, YP | 1 |
| Abuirmeileh, A | 1 |
| Kingsbury, AE | 1 |
| Lees, AJ | 1 |
| Locke, IC | 1 |
| Knight, RA | 1 |
| Chowdrey, HS | 1 |
| Biggs, CS | 1 |
| Newcomb, JD | 1 |
| Janowski, M | 1 |
| Zigova, T | 1 |
| Saporta, S | 4 |
| McGrogan, MP | 1 |
| Sanberg, PR | 5 |
| Willing, AE | 1 |
| Wang, DQ | 1 |
| Jing, FC | 1 |
| Miklyaeva, EI | 5 |
| Whishaw, IQ | 6 |
| Kolb, B | 1 |
| Senthilkumar, KS | 1 |
| Saravanan, KS | 1 |
| Chandra, G | 1 |
| Sindhu, KM | 1 |
| Jayakrishnan, A | 1 |
| Mohanakumar, KP | 1 |
| Heise, CE | 1 |
| Reyes, S | 1 |
| Mitrofanis, J | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Lane, E | 1 |
| Dunnett, S | 1 |
| Cassano, T | 1 |
| Cuomo, V | 1 |
| Hozumi, H | 1 |
| Miyoshi, K | 1 |
| Sogawa, N | 1 |
| Ebert, AD | 1 |
| Beres, AJ | 1 |
| Barber, AE | 1 |
| Svendsen, CN | 2 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Esposito, E | 1 |
| Fantin, M | 1 |
| Marti, M | 2 |
| Drechsler, M | 1 |
| Paccamiccio, L | 1 |
| Mariani, P | 1 |
| Sivieri, E | 1 |
| Lain, F | 1 |
| Menegatti, E | 1 |
| Morari, M | 2 |
| Cortesi, R | 1 |
| Crotty, S | 1 |
| Fitzgerald, P | 1 |
| Tuohy, E | 1 |
| Harris, DM | 1 |
| Fisher, A | 1 |
| Mandel, A | 1 |
| Bolton, AE | 1 |
| Sullivan, AM | 2 |
| Nolan, Y | 1 |
| Lee, YM | 1 |
| Park, SH | 1 |
| Shin, DI | 1 |
| Hwang, JY | 1 |
| Park, B | 1 |
| Park, YJ | 1 |
| Lee, TH | 1 |
| Chae, HZ | 1 |
| Oh, TH | 1 |
| Oh, YJ | 1 |
| Bouchez, G | 1 |
| Sensebé, L | 1 |
| Vourc'h, P | 1 |
| Garreau, L | 1 |
| Bodard, S | 1 |
| Rico, A | 1 |
| Guilloteau, D | 1 |
| Charbord, P | 1 |
| Besnard, JC | 1 |
| Chalon, S | 1 |
| van Dijk, A | 1 |
| Johnston, C | 1 |
| Allbutt, H | 1 |
| Henderson, J | 1 |
| Zhou, FW | 1 |
| Battefeld, A | 1 |
| Köhling, R | 1 |
| Badavi, M | 1 |
| Hoseiny, N | 1 |
| Gharibnaseri, MK | 1 |
| Rahim, F | 1 |
| Hefti, F | 1 |
| Breese, GR | 1 |
| Baumeister, AA | 1 |
| McCown, TJ | 1 |
| Emerick, SG | 1 |
| Frye, GD | 1 |
| Crotty, K | 1 |
| Mueller, RA | 1 |
| Atadzhanov, M | 1 |
| Anton, R | 1 |
| Kordower, JH | 1 |
| Manaster, JS | 1 |
| Kane, DJ | 1 |
| Rabizadeh, S | 2 |
| Schueller, SB | 1 |
| Yang, J | 1 |
| Edwards, RH | 1 |
| van Muiswinkel, FL | 1 |
| Drukarch, B | 1 |
| de Vente, J | 1 |
| Martens, DJ | 1 |
| Carey, RJ | 4 |
| Dai, H | 3 |
| Pinheiro-Carrera, M | 2 |
| Tomaz, C | 2 |
| Fornaguera, J | 2 |
| Boix, F | 1 |
| Morley, JS | 1 |
| Bazzaz, AA | 1 |
| Ensor, DM | 1 |
| Miles, JB | 1 |
| Kaplitt, MG | 1 |
| Leone, P | 2 |
| Samulski, RJ | 1 |
| Xiao, X | 1 |
| Pfaff, DW | 1 |
| During, MJ | 2 |
| Papa, SM | 2 |
| Engber, TM | 2 |
| Kask, AM | 2 |
| Spector, DH | 1 |
| Boss, BD | 1 |
| Strecker, RE | 2 |
| Plunkett, RJ | 2 |
| Oldfield, EH | 2 |
| Sakai, K | 1 |
| Gash, DM | 3 |
| Cunningham, MG | 1 |
| Jödicke, A | 2 |
| Knappe, U | 2 |
| Belluzzi, JD | 1 |
| Domino, EF | 1 |
| May, JM | 1 |
| McAfee, DA | 1 |
| Thomas, J | 1 |
| Takubo, H | 1 |
| Sheng, J | 1 |
| de Jesus, S | 1 |
| Richard, MG | 1 |
| Bennett, JP | 3 |
| De Klippel, N | 1 |
| Herregodts, P | 1 |
| Ebinger, G | 1 |
| Sato, K | 2 |
| Ueda, H | 2 |
| Okumura, F | 2 |
| Misu, Y | 2 |
| McRae, A | 1 |
| Dahlström, A | 1 |
| Kondoh, T | 1 |
| Blount, JP | 1 |
| Conrad, JA | 1 |
| Pundt, LL | 1 |
| Low, WC | 1 |
| Sauer, H | 4 |
| Campbell, K | 1 |
| Wiegand, SJ | 1 |
| Lindsay, RM | 1 |
| Fisher, LJ | 1 |
| Gage, FH | 2 |
| Mercuri, NB | 1 |
| Sancesario, G | 1 |
| Jiao, S | 1 |
| Gurevich, V | 1 |
| Wolff, JA | 1 |
| Basso, MA | 2 |
| Evinger, C | 2 |
| Curran, EJ | 1 |
| Becker, JB | 3 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Youdim, MB | 1 |
| Ben-Shachar, D | 1 |
| Eshel, G | 1 |
| Riederer, P | 1 |
| Kopin, IJ | 2 |
| Jacobowitz, DM | 2 |
| Cole, DG | 1 |
| Growdon, JH | 1 |
| DiFiglia, M | 1 |
| Stauch Slusher, B | 1 |
| Rissolo, KC | 1 |
| Anzilotti, KF | 1 |
| Jackson, PF | 1 |
| Nakao, N | 1 |
| Uematsu, Y | 1 |
| Komai, N | 2 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Bedard, PJ | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 1 |
| Robertson, GS | 1 |
| Kurokawa, M | 2 |
| Koga, K | 2 |
| Kase, H | 1 |
| Nakamura, J | 2 |
| Kuwana, Y | 2 |
| Ishida, Y | 3 |
| Hashiguchi, H | 3 |
| Todaka, K | 3 |
| Kuwahara, I | 3 |
| Mitsuyama, Y | 3 |
| Nishimori, T | 2 |
| Tien, LT | 2 |
| Lapchak, PA | 1 |
| Mokrý, J | 1 |
| Mazadier, M | 1 |
| Miquet, JM | 1 |
| Parmentier, S | 1 |
| Dubédat, P | 1 |
| Doble, A | 1 |
| Boireau, A | 1 |
| He, Y | 3 |
| Thong, PS | 1 |
| Lee, T | 3 |
| Leong, SK | 3 |
| Shi, CY | 1 |
| Wong, PT | 1 |
| Yuan, SY | 1 |
| Watt, F | 1 |
| Cintra, A | 1 |
| Andbjer, B | 2 |
| Finnman, UB | 1 |
| Hagman, M | 1 |
| Agnati, LF | 1 |
| Höglund, G | 1 |
| Fuxe, K | 3 |
| Boldry, RC | 1 |
| Winkler, C | 4 |
| Lee, CS | 1 |
| Mendez, I | 4 |
| Sadi, D | 2 |
| Hong, M | 4 |
| Powers, AS | 1 |
| Hattori, S | 1 |
| Hashitani, T | 2 |
| Matsui, N | 1 |
| Nishino, H | 2 |
| Möller, JC | 1 |
| Sautter, J | 4 |
| Kupsch, A | 2 |
| Coles, BL | 1 |
| Pellis, SM | 1 |
| Rozas, G | 2 |
| Labandeira García, JL | 1 |
| Michaelides, MR | 1 |
| Hong, Y | 1 |
| DiDomenico, S | 1 |
| Bayburt, EK | 1 |
| Asin, KE | 1 |
| Britton, DR | 2 |
| Lin, CW | 1 |
| Shiosaki, K | 1 |
| Löschmann, PA | 4 |
| Wüllner, U | 1 |
| Heneka, MT | 1 |
| Kunow, M | 4 |
| Wachtel, H | 4 |
| Klockgether, T | 1 |
| Schwarz, SC | 2 |
| Oertel, WH | 5 |
| Earl, CD | 2 |
| Kupsch, AR | 1 |
| Matsuura, K | 1 |
| Makino, H | 1 |
| Gerhardt, GA | 1 |
| Othberg, AI | 1 |
| Freeman, TB | 1 |
| Cameron, DF | 2 |
| Opacka-Juffry, J | 1 |
| Hötten, G | 1 |
| Pohl, J | 1 |
| Blunt, SB | 2 |
| Spratt, SK | 1 |
| Snyder, RO | 2 |
| Leff, SE | 2 |
| Horellou, P | 1 |
| Mallet, J | 1 |
| Caldwell, MA | 1 |
| Shen, J | 1 |
| ter Borg, MG | 1 |
| Karmiol, S | 1 |
| Woodward, NC | 1 |
| Nikiforov, EG | 1 |
| Tompkins, GJ | 1 |
| Klassen, F | 1 |
| Ioffe, ME | 1 |
| Van Keuren, KR | 1 |
| Stodgell, CJ | 1 |
| Schroeder, SR | 1 |
| Tessel, RE | 1 |
| Espejo, EF | 2 |
| Montoro, RJ | 1 |
| Armengol, JA | 1 |
| López-Barneo, J | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Yahr, MD | 1 |
| Tang, FI | 1 |
| Zhou, FC | 1 |
| Mizukawa, K | 1 |
| Kumazaki, M | 1 |
| Fox, SH | 2 |
| Moser, B | 1 |
| Murer, MG | 2 |
| Dziewczapolski, G | 1 |
| Menalled, LB | 1 |
| García, MC | 1 |
| Agid, Y | 2 |
| Gershanik, O | 1 |
| Raisman-Vozari, R | 1 |
| Imaoka, T | 1 |
| Ohmoto, T | 1 |
| Nagatsu, T | 1 |
| Mehta, V | 1 |
| Spears, J | 1 |
| Schwarz, J | 1 |
| Henry, B | 2 |
| Crossman, AR | 3 |
| Schierle, GS | 1 |
| Karlsson, J | 1 |
| Horger, BA | 1 |
| Nishimura, MC | 1 |
| Armanini, MP | 1 |
| Wang, LC | 1 |
| Poulsen, KT | 1 |
| Moffat, B | 2 |
| Simmons, L | 1 |
| Johnson, E | 1 |
| Milbrandt, J | 1 |
| Rosenthal, A | 1 |
| Vandlen, RA | 1 |
| Hynes, MA | 1 |
| Phillips, HS | 2 |
| Hirata, H | 1 |
| Cadet, JL | 4 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Pavón, N | 2 |
| Vidal, L | 2 |
| Alvarez, P | 1 |
| Blanco, L | 2 |
| Torres, A | 1 |
| Rodríguez, A | 1 |
| Macías, R | 2 |
| Samii, M | 2 |
| Huang, KX | 1 |
| Bergstrom, DA | 1 |
| Ruskin, DN | 1 |
| Walters, JR | 1 |
| Sladek, JR | 1 |
| Mura, A | 2 |
| Feldon, J | 2 |
| Mintz, M | 2 |
| Ishizuka, Y | 1 |
| Alvarez-Fonseca, P | 1 |
| Castellano, O | 1 |
| Castillo, L | 1 |
| García, A | 1 |
| Rosillo, JC | 1 |
| Jiang, ZH | 1 |
| Ni, ZM | 1 |
| Zhou, CF | 1 |
| Cao, L | 1 |
| Zheng, ZC | 1 |
| Zhao, YC | 1 |
| Volenec, A | 1 |
| Zetterström, TS | 1 |
| Flanigan, TP | 1 |
| Dodel, RC | 1 |
| Du, Y | 1 |
| Bales, KR | 1 |
| Ling, Z | 1 |
| Carvey, PM | 1 |
| Paul, SM | 1 |
| Sbrenna, S | 1 |
| Bianchi, C | 1 |
| Beani, L | 1 |
| Vergara, P | 2 |
| Brenner, M | 2 |
| Vaughan, CL | 1 |
| Bentlage, C | 1 |
| Lamensdorf, I | 1 |
| Meiri, N | 1 |
| Chang, JW | 1 |
| Wachtel, SR | 1 |
| Young, D | 1 |
| Kang, UJ | 1 |
| Devaux, B | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Hironishi, M | 1 |
| Ueyama, E | 1 |
| Senba, E | 1 |
| Woodgate, A | 1 |
| MacGibbon, G | 1 |
| Walton, M | 1 |
| Dragunow, M | 1 |
| Tang, Z | 1 |
| Ying, Q | 1 |
| Peng, L | 1 |
| Tian, J | 1 |
| Gresch, PJ | 2 |
| Muir, GD | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Khalil, EM | 1 |
| Pradhan, A | 1 |
| Ojala, WH | 1 |
| Gleason, WB | 1 |
| Mishra, RK | 1 |
| Johnson, RL | 1 |
| Annett, LE | 1 |
| Ryan, LJ | 1 |
| Chiang, W | 1 |
| Hidaka, S | 1 |
| Torres, EM | 1 |
| Trejo, F | 1 |
| Tolwani, RJ | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Jiménez, A | 1 |
| Dunah, AW | 1 |
| Yasuda, RP | 1 |
| Kameyama, K | 1 |
| Huganir, RL | 1 |
| Wolfe, BB | 1 |
| Kim, BG | 1 |
| Shin, DH | 2 |
| Jeon, GS | 1 |
| Seo, JH | 1 |
| Kim, YW | 1 |
| Jeon, BS | 1 |
| Cho, SS | 1 |
| Ben, V | 2 |
| Blin, O | 1 |
| Bruguerolle, B | 2 |
| Yurek, DM | 2 |
| Fletcher-Turner, A | 1 |
| Vila, M | 1 |
| Féger, J | 2 |
| Hirsch, EC | 1 |
| Collins, P | 1 |
| Wilkinson, LS | 1 |
| Everitt, BJ | 1 |
| Robbins, TW | 1 |
| Roberts, AC | 1 |
| Baker, KA | 2 |
| Guzman, R | 1 |
| Lövblad, KO | 1 |
| Meyer, M | 2 |
| Spenger, C | 2 |
| Schroth, G | 1 |
| Widmer, HR | 2 |
| Ratcliffe, E | 1 |
| McLaughlin, M | 1 |
| Schelkun, RM | 1 |
| Yuen, PW | 1 |
| Serpa, K | 1 |
| Meltzer, LT | 1 |
| Wise, LD | 1 |
| Whittemore, ER | 1 |
| Woodward, RM | 1 |
| McPhee, SW | 1 |
| Janson, CG | 1 |
| Davidson, BL | 1 |
| Freese, A | 1 |
| Seroogy, KB | 1 |
| Bensadoun, JC | 1 |
| Déglon, N | 1 |
| Tseng, JL | 1 |
| Ridet, JL | 1 |
| Zurn, AD | 1 |
| Aebischer, P | 2 |
| Höglinger, GU | 2 |
| Törnqvist, N | 1 |
| Björklund, L | 1 |
| Almqvist, P | 1 |
| Wahlberg, L | 2 |
| Strömberg, I | 3 |
| Kehr, J | 1 |
| Cragg, SJ | 1 |
| Clarke, DJ | 2 |
| Greenfield, SA | 1 |
| Bordet, R | 1 |
| Ridray, S | 1 |
| Schwartz, JC | 1 |
| Sokoloff, P | 1 |
| Andringa, G | 1 |
| van Oosten, RV | 2 |
| Unger, W | 1 |
| Hafmans, TG | 1 |
| Veening, J | 1 |
| Stoof, JC | 1 |
| Cools, AR | 2 |
| Lamango, NS | 1 |
| Charlton, CG | 1 |
| Ochi, M | 1 |
| Johnson, RE | 1 |
| Dabbeni-Sala, F | 1 |
| Franceschini, D | 1 |
| Skaper, SD | 1 |
| Costa, G | 1 |
| Abin-Carriquiry, JA | 1 |
| Dajas, F | 1 |
| Seiler, RW | 1 |
| Costantini, LC | 1 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Rodríguez Díaz, M | 1 |
| Abdala, P | 2 |
| Barroso-Chinea, P | 2 |
| Obeso, J | 2 |
| González-Hernández, T | 2 |
| Camargo, MD | 1 |
| Pitzer, MR | 1 |
| Gyawali, S | 1 |
| Connor, B | 1 |
| Kozlowski, DA | 1 |
| Unnerstall, JR | 1 |
| Bohn, MC | 1 |
| Pirker, W | 1 |
| Pontén, H | 1 |
| Hurd, YL | 1 |
| Datla, KP | 1 |
| Philhower, J | 1 |
| Miller, GW | 1 |
| Steiner, JP | 1 |
| Hamilton, GS | 1 |
| Hicks, TP | 1 |
| Poulter, MO | 1 |
| Tseng, KY | 1 |
| Kasanetz, F | 1 |
| Kargieman, L | 1 |
| Riquelme, LA | 1 |
| Chen, MT | 1 |
| Woodward, DJ | 1 |
| Janak, PH | 1 |
| Akerud, P | 1 |
| Canals, JM | 1 |
| Arenas, E | 1 |
| Boules, M | 1 |
| Warrington, L | 1 |
| Fauq, A | 1 |
| McCormick, D | 1 |
| Richelson, E | 1 |
| Gonzalez-Albo, MC | 1 |
| Moraes, JP | 1 |
| El Banoua, F | 1 |
| Caraballo, I | 1 |
| Andersson, M | 2 |
| Konradi, C | 1 |
| Hassani, OK | 1 |
| Mouroux, M | 1 |
| Bohme, GA | 1 |
| Stutzmann, JM | 1 |
| Tsuboi, K | 1 |
| Shults, CW | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Riobó, NA | 1 |
| Schöpfer, FJ | 1 |
| Boveris, AD | 1 |
| Cadenas, E | 1 |
| Poderoso, JJ | 1 |
| Fredduzzi, S | 1 |
| Monopoli, A | 1 |
| Cuellar, B | 1 |
| Xu, K | 1 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Lundblad, M | 1 |
| Wierup, N | 1 |
| Cunningham, LA | 1 |
| Su, C | 1 |
| Cai, D | 1 |
| Oo, TF | 1 |
| Siman, R | 1 |
| Burke, RE | 1 |
| Hurelbrink, CB | 1 |
| Ratcliffe, EL | 1 |
| Kamel, D | 1 |
| Moore, C | 1 |
| Kay, TS | 1 |
| Krentz, L | 1 |
| Frodl, EM | 1 |
| ten Bruggencate, G | 1 |
| Kebabian, JW | 1 |
| DeNinno, MP | 1 |
| Perner, R | 1 |
| Smith, L | 1 |
| Jenner, P | 3 |
| Schoenleber, R | 1 |
| Williams, M | 1 |
| Silverman, PB | 1 |
| Fenu, S | 1 |
| Di Chiara, G | 2 |
| Heikkila, RE | 1 |
| Sonsalla, PK | 1 |
| Walters, AM | 1 |
| Bradford, HF | 1 |
| Stern, GM | 1 |
| Matsuda, S | 1 |
| Saito, H | 1 |
| Nishiyama, N | 1 |
| Zhu, SM | 2 |
| Hall, S | 1 |
| Rutledge, JN | 1 |
| Kujirai, K | 1 |
| Dollison, A | 1 |
| Angulo, J | 1 |
| Fahn, S | 2 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Hastings, TG | 1 |
| Abercrombie, ED | 1 |
| Friehs, GM | 1 |
| Parker, RG | 1 |
| He, LS | 1 |
| Haines, SJ | 1 |
| Turner, DA | 1 |
| Ebner, TJ | 1 |
| Takeuchi, Y | 1 |
| Sawada, T | 1 |
| Blunt, S | 1 |
| Marsden, CD | 2 |
| Orosz, D | 1 |
| Jicha, GA | 1 |
| Salamone, JD | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Lange, KW | 1 |
| Rettig, KJ | 1 |
| Jähnig, P | 1 |
| Honoré, T | 1 |
| Turski, L | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Jiang, D | 1 |
| Graham, WC | 1 |
| Woodruff, GN | 1 |
| Dymecki, J | 3 |
| Freed, WJ | 3 |
| Kaakkola, S | 1 |
| Teräväinen, H | 1 |
| Torigoe, R | 1 |
| Yoshida, M | 1 |
| Ohtsuru, K | 1 |
| Kuga, S | 1 |
| Berger, TW | 1 |
| Grace, AA | 1 |
| Stricker, EM | 2 |
| Winn, SR | 1 |
| Tresco, PA | 1 |
| Perese, DA | 1 |
| Ulman, J | 1 |
| Viola, J | 1 |
| Ewing, SE | 1 |
| Bygdeman, M | 1 |
| Goldstein, M | 1 |
| Seiger, A | 1 |
| Olson, L | 1 |
| Kamo, H | 1 |
| Kim, SU | 1 |
| McGeer, PL | 1 |
| Xu, DL | 1 |
| Yu, WC | 1 |
| Pan, GB | 1 |
| Cohen, G | 1 |
| Kenny, AM | 1 |
| Schneider, MB | 1 |
| Baden, DR | 1 |
| Pfeiffer, RF | 1 |
| Murrin, LC | 1 |
| Frei, B | 1 |
| Richter, C | 1 |
| Burunat, E | 1 |
| Castro, R | 1 |
| Díaz-Palarea, MD | 1 |
| Kamei, I | 1 |
| Naka, Y | 1 |
| Nakakita, K | 1 |
| Imai, H | 1 |
| Caccia, C | 1 |
| Achilli, G | 1 |
| Buonamici, M | 1 |
| Carpentieri, M | 1 |
| Cervini, MA | 1 |
| Maj, R | 1 |
| Pegrassi, L | 1 |
| Rossi, AC | 1 |
| Pezzoli, G | 1 |
| Dwork, A | 1 |
| Truong, DD | 1 |
| de Yebenes, JG | 1 |
| Jackson-Lewis, V | 1 |
| Herbert, J | 1 |
| Hansen, JT | 1 |
| Bing, GY | 1 |
| Notter, MF | 1 |
| Nilsson, OG | 1 |
| Półtorak, M | 1 |
| Puciłowski, O | 1 |
| Markiewicz, D | 1 |
| Kostowski, W | 1 |
| Snyder, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| Neuroactive Steroids in Acute Ischemic Stroke: Association With Cognitive, Functional and Neurological Outcomes.[NCT02914106] | 60 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke[NCT03242304] | 40 participants (Actual) | Observational | 2016-04-01 | Completed | |||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease[NCT01621581] | Phase 1 | 25 participants (Actual) | Interventional | 2013-03-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
30 reviews available for oxidopamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2020 |
Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?
Topics: Animals; Humans; Methamphetamine; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine | 2014 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine | 2009 |
Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models.
Topics: Animals; Biomarkers; Cell Death; Central Nervous System; Free Radicals; Humans; MPTP Poisoning; Oxid | 2010 |
Neurotoxic in vivo models of Parkinson's disease recent advances.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; MPTP Poisoning; Neurotoxicity Syndromes; Neurotox | 2010 |
Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease.
Topics: Animals; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Learning; M | 2010 |
Modeling neuroinflammatory pathogenesis of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dopamine; Humans; Inflammation; Lipopolysaccha | 2010 |
Neurotoxin-based models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, | 2012 |
A guide to neurotoxic animal models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Haplorhini; Lewy Bodies; Mice; MPTP Poisoning; Neu | 2011 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modifie | 2012 |
Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Disease Models, Animal; Feeding Behavior; Mice; M | 2012 |
Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Genetic Vectors; Humans; Oxidopamine; Parkinson Di | 2012 |
Modeling dyskinesia in animal models of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; MPTP Poisoning; Oxi | 2014 |
Can the brain be protected through exercise? Lessons from an animal model of parkinsonism.
Topics: Animals; Glial Cell Line-Derived Neurotrophic Factor; Humans; Nerve Growth Factors; Oxidopamine; Par | 2003 |
Toxin-induced models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Herbicides; Humans; Neurotox | 2005 |
Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Humans; Nerve Dege | 2006 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Dr | 2008 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; | 1993 |
Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Basal Ganglia; Brain Tissue | 1993 |
Experimental models and behavioural tests used in the study of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Motor Activity; Nerve Tissue; Oxidopamine; Parkin | 1995 |
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine Agonists; Functional Laterality; Humans; Levodopa; Mo | 1996 |
Potential of neurotrophic factors in therapy of Parkinson's disease.
Topics: Adrenal Medulla; Animals; Cells, Cultured; Dopamine; Drug Evaluation, Preclinical; Drug Synergism; G | 1996 |
Gene therapy for Parkinson's disease.
Topics: Adenoviruses, Human; Animals; Astrocytes; Cell Survival; Cell Transplantation; Cells, Cultured; Corp | 1997 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Survival; Corpus Striatum; | 2000 |
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Eval | 1992 |
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Pa | 1992 |
Animal models of parkinsonism.
Topics: Aging; Animals; Behavior, Animal; Disease Models, Animal; Hydroxydopamines; MPTP Poisoning; Oxidopam | 1990 |
Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hydroxydopamines; Neurotoxins; Oxidopamine; Parkin | 1989 |
607 other studies available for oxidopamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; GABAergic Neurons; Humans; Levodopa; Male; Ox | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic N | 2021 |
L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Topics: Animals; Cell Movement; Corpus Striatum; Dopaminergic Neurons; Drug Interactions; Embryo, Mammalian; | 2021 |
The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Humans; Mice; Neuroprotective Agents; Oxidopa | 2021 |
Early Repetitive Transcranial Magnetic Stimulation Exerts Neuroprotective Effects and Improves Motor Functions in Hemiparkinsonian Rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Gait; Male; Motor Cortex; Mo | 2021 |
Aerobic exercise improves motor function and striatal MSNs-Erk/MAPK signaling in mice with 6-OHDA-induced Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Extracellular Sign | 2022 |
Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Lipopolysaccharides; Male; M | 2020 |
The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study.
Topics: Aged; Aged, 80 and over; Animals; Behavior Observation Techniques; Behavior, Animal; Case-Control St | 2019 |
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Lignans; Male; Neuroprotecti | 2020 |
Immature mDA neurons ameliorate motor deficits in a 6-OHDA Parkinson's disease mouse model and are functional after cryopreservation.
Topics: Animals; Cell Differentiation; Cell Line; Cryopreservation; Dopaminergic Neurons; Heterografts; Huma | 2019 |
Regular Aerobic Exercise-Alleviated Dysregulation of CAMKIIα Carbonylation to Mitigate Parkinsonism via Homeostasis of Apoptosis With Autophagy.
Topics: Aging; alpha-Synuclein; Animals; Apoptosis; Autophagy; Beclin-1; Behavior, Animal; Calcium-Binding P | 2020 |
Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrophic Facto | 2020 |
The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
Topics: Animals; Corpus Striatum; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Fragmentat | 2020 |
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosa | 2020 |
Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain; Disease Models, Animal; Dopamine; Hypoglossal Nerve; Hypoxia; Mal | 2020 |
Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Topics: Aging; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Hum | 2020 |
Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Cytokines; Depression; Dopaminergic Neurons; He | 2020 |
Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.
Topics: Animals; Cardiotonic Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Heart Rate; Male; Ne | 2020 |
Polyphenols from Toona sinensiss Seeds Alleviate Neuroinflammation Induced by 6-Hydroxydopamine Through Suppressing p38 MAPK Signaling Pathway in a Rat Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Cyclooxygenase 2; Dopaminergic Neurons; Inflammation; | 2020 |
Loss of Collapsin Response Mediator Protein 4 Attenuates 6-Hydroxydopamine-Induced Impairments in a Mouse Model of Parkinson's Disease.
Topics: Animals; Caspase 3; Cyclooxygenase 2; Dopaminergic Neurons; Gene Deletion; Genetic Therapy; Male; Mi | 2020 |
Xanthotoxin reverses Parkinson's disease-like symptoms in zebrafish larvae and mice models: a comparative study.
Topics: Animals; Antiparkinson Agents; Biological Assay; Drug Discovery; Fruit; Larva; Male; Methoxsalen; Mi | 2021 |
Protective effects of Nrf2-ARE activator on dopaminergic neuronal loss in Parkinson disease model mice: Possible involvement of heme oxygenase-1.
Topics: Animals; Antioxidant Response Elements; Cell Death; Corpus Striatum; Dopaminergic Neurons; Heme Oxyg | 2020 |
Evaluation of
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Autoradiography; Brain; Disease Models, Animal; | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levod | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopedun | 2020 |
Increased energy expenditure and activated β3-AR-cAMP-PKA signaling pathway in the interscapular brown adipose tissue of 6-OHDA-induced Parkinson's disease model rats.
Topics: Adipose Tissue, Brown; Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Energy Metabolism; | 2021 |
The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Benzaldehydes; Corpus Striatum; Disease Models, Animal; Dopamine; Immunoh | 2020 |
Transplanted Wharton's jelly mesenchymal stem cells improve memory and brain hippocampal electrophysiology in rat model of Parkinson's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Hippocampus; Lo | 2020 |
Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Corpus Striatum; Curcumin; Disease Models, Animal; | 2020 |
Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Behavior, Animal; Discrimination Learning; Dopam | 2021 |
Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson's disease.
Topics: Apolipoproteins D; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Celecoxib; Cell Line | 2021 |
Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats.
Topics: Animals; Disks Large Homolog 4 Protein; Hippocampus; Intercellular Signaling Peptides and Proteins; | 2021 |
MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson's Disease Models by Directly Targeting MEF2D.
Topics: Animals; bcl-2-Associated X Protein; Binding Sites; Cell Death; Cell Line; Dopaminergic Neurons; MEF | 2021 |
Neuroprotective Effects of Safflower Flavonoid Extract in 6-Hydroxydopamine-Induced Model of Parkinson's Disease May Be Related to its Anti-Inflammatory Action.
Topics: Animals; Anti-Inflammatory Agents; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Brain; Cart | 2020 |
Cell Type-Specific Oxidative Stress Genomic Signatures in the Globus Pallidus of Dopamine-Depleted Mice.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Globus Pallidus; Mice; Mice, Transgenic; Neurons; Oxidati | 2020 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic | 2021 |
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease.
Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Seconda | 2021 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; | 2021 |
Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson's disease: motor and non-motor outcomes.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Garlic; Male; Motor Activity; Neuroprotective | 2021 |
Behavior and oxidative stress parameters in rats subjected to the animal's models induced by chronic mild stress and 6-hydroxydopamine.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Brain; Corpus Striatum; Depressive Disorder, Major; Di | 2021 |
Striatal Direct Pathway Targets Npas1
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Female; Globus Pallidus; Locomotion; Male; Mi | 2021 |
Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Gene Knockdown Techniques; HeLa | 2021 |
Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants in Parkinsonian rats.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Engineering; Cell Line; Cell Proliferation; Disease M | 2021 |
Fractionating stem cells secretome for Parkinson's disease modeling: Is it the whole better than the sum of its parts?
Topics: Animals; Bone Marrow Cells; Disease Models, Animal; Extracellular Vesicles; Humans; Male; Mesenchyma | 2021 |
Mechanism for antiParkinsonian effect of resveratrol: Involvement of transporters, synaptic proteins, dendrite arborization, biochemical alterations, ER stress and apoptosis.
Topics: Animals; Antiparkinson Agents; Apoptosis; Dendrites; Disks Large Homolog 4 Protein; Dopamine Plasma | 2021 |
Transcriptome profiling of five brain regions in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Brain Chemistry; Computational Biology; Dopaminergic Neurons; Endocannabinoids; G Protein-C | 2021 |
Reduced acetylcholine and elevated muscarinic receptor 2 in duodenal mucosa contribute to the impairment of mucus secretion in 6-hydroxydopamine-induced Parkinson's disease rats.
Topics: Acetylcholine; Animals; Duodenum; Intestinal Mucosa; Male; Mucus; Oxidopamine; Parkinson Disease, Se | 2021 |
High-fat diet-induced diabetes leads to vascular alterations, pericyte reduction, and perivascular depletion of microglia in a 6-OHDA toxin model of Parkinson disease.
Topics: Amphetamine; Animals; Behavior, Animal; Blood-Brain Barrier; Corpus Striatum; Diabetes Mellitus, Typ | 2021 |
Disrupted basal ganglia output during movement preparation in hemiparkinsonian mice is consistent with behavioral deficits.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL | 2021 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Med | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, D | 2017 |
Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Glutamic Acid; | 2017 |
The Neuroprotective Role of MiR-124-3p in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via the Regulation of ANAX5.
Topics: Animals; Annexin A5; Gene Expression Regulation; MicroRNAs; Models, Biological; Neuroprotection; Oxi | 2018 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dru | 2017 |
Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dependovirus; Genetic Therapy; Human | 2017 |
6-OHDA Induces Oxidation of F-box Protein Fbw7β by Chaperone-Mediated Autophagy in Parkinson's Model.
Topics: Aged; Aged, 80 and over; Animals; Autophagy; Cell Line; Dopaminergic Neurons; F-Box-WD Repeat-Contai | 2018 |
Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cystathionine beta-Synthase; Disease Models, Animal; H | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephal | 2017 |
Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle.
Topics: Animals; Behavior, Animal; Depressive Disorder; Dopamine; Male; Medial Forebrain Bundle; Norepinephr | 2017 |
Brown adipose tissue activation in a rat model of Parkinson's disease.
Topics: Adipose Tissue, Brown; Animals; Cold Temperature; Denervation; Male; Oxidopamine; Parkinson Disease, | 2017 |
Effects of Electroacupuncture on Metabolic Changes in Motor Cortex and Striatum of 6-Hydroxydopamine-Induced Parkinsonian Rats.
Topics: Animals; Corpus Striatum; Electroacupuncture; Male; Motor Activity; Motor Cortex; Oxidopamine; Parki | 2020 |
6-Hydroxydopamine induces brain vascular endothelial inflammation.
Topics: Animals; Brain; Cell Adhesion; Coculture Techniques; Cyclooxygenase 2; Disease Models, Animal; E-Sel | 2017 |
Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Flavonoids; Gene Expression Regulatio | 2018 |
Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats.
Topics: Animals; Glutamates; Locomotion; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease | 2018 |
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne | 2018 |
Treadmill Exercise Improves Motor Dysfunction and Hyperactivity of the Corticostriatal Glutamatergic Pathway in Rats with 6-OHDA-Induced Parkinson's Disease.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Male; Motor Activity; Neural Pathways; Oxidopamine; Parki | 2017 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cor | 2018 |
Analysis of respiratory movements in a mouse model of late Parkinson's disease submitted to stress.
Topics: Animals; Apomorphine; Cineradiography; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; L | 2018 |
Electroacupuncture Alleviates Motor Symptoms and Up-Regulates Vesicular Glutamatergic Transporter 1 Expression in the Subthalamic Nucleus in a Unilateral 6-Hydroxydopamine-Lesioned Hemi-Parkinsonian Rat Model.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dopamine Agonists; Electroacupunctu | 2018 |
Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity.
Topics: Animals; Dopamine; Glucosides; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidopamine; P | 2018 |
Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.
Topics: Animals; Apomorphine; Biomarkers; Cell Death; Dopamine; Dopamine Agonists; Male; Neurons; Oxidative | 2018 |
Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo.
Topics: Animals; Apoptosis; Astrocytes; Disease Models, Animal; Dopaminergic Neurons; Humans; Membrane Glyco | 2018 |
Salidroside Protection Against Oxidative Stress Injury Through the Wnt/β-Catenin Signaling Pathway in Rats with Parkinson's Disease.
Topics: Animals; Antioxidants; Apoptosis; Female; Glucosides; Male; Neuroprotective Agents; Oxidative Stress | 2018 |
Nitric oxide alterations in cardiovascular system of rats with Parkinsonism induced by 6-OHDA and submitted to previous exercise.
Topics: Animals; Arterial Pressure; Cardiovascular System; Dopamine; Enzyme Inhibitors; Heart Rate; Male; Ne | 2018 |
Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Topics: Adamantane; Animals; Behavior, Animal; Dipeptides; Disease Models, Animal; Dopaminergic Neurons; Mal | 2018 |
Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Dopamine; Functional Laterality; Hyperalgesia; H | 2018 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
Disruption of the Circadian Clock Alters Antioxidative Defense via the SIRT1-BMAL1 Pathway in 6-OHDA-Induced Models of Parkinson's Disease.
Topics: Animals; Antioxidants; ARNTL Transcription Factors; Circadian Clocks; Male; Oxidopamine; Parkinson D | 2018 |
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
Topics: Animals; Apomorphine; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Lignans; Male; Mi | 2018 |
Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Cell Differentiation; Corpus Striatum; Disease | 2018 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Delayed-Action Preparations; | 2018 |
Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dopaminergic Neurons; Mal | 2019 |
NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
Topics: Acetophenones; Animals; Apomorphine; Cell Line, Transformed; Corpus Striatum; Disease Models, Animal | 2018 |
Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/β-catenin signaling in rat model of Parkinson's disease.
Topics: Adaptor Proteins, Signal Transducing; Animals; Basic Helix-Loop-Helix Transcription Factors; beta Ca | 2018 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-I | 2018 |
Glycyrrhizic Acid Alleviates 6-Hydroxydopamine and Corticosterone-Induced Neurotoxicity in SH-SY5Y Cells Through Modulating Autophagy.
Topics: alpha-Synuclein; Apoptosis; Autophagy; Beclin-1; Brain-Derived Neurotrophic Factor; Cell Line, Tumor | 2018 |
Intrapallidal injection of botulinum toxin A recovers gait deficits in a parkinsonian rodent model.
Topics: Animals; Botulinum Toxins, Type A; Entopeduncular Nucleus; Gait Disorders, Neurologic; Oxidopamine; | 2019 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/α-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.
Topics: alpha-Synuclein; Apoptosis; Cell Line, Tumor; Down-Regulation; Humans; Leucine-Rich Repeat Serine-Th | 2019 |
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.
Topics: Animals; Dopaminergic Neurons; Female; Male; Mice; Motor Skills; Neuroprotective Agents; Oxidopamine | 2019 |
Respiratory disturbances in a mouse model of Parkinson's disease.
Topics: Animals; Biomechanical Phenomena; Collagen; Hypercapnia; Lung; Male; Mice; Mice, Inbred C57BL; Micro | 2019 |
Optogenetic Stimulation of the M2 Cortex Reverts Motor Dysfunction in a Mouse Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Male; Mice; Motor Cortex; Motor Skills; Optogenetics; Oxidopamine; | 2019 |
Effects of Preventive Treadmill Exercise on the Recovery of Metabolic and Mitochondrial Factors in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Brain; Disease Models, Animal; Exercise Test; Male; Mitochondria; Oxidopamine; Parkinson Di | 2019 |
Dopaminergic urethral closure mechanisms in a rat model of Parkinson's disease.
Topics: Animals; Dopamine Agents; Electric Stimulation; Female; Oxidopamine; Parkinson Disease, Secondary; R | 2019 |
Dereplication of Components Coupled with HPLC-qTOF-MS in the Active Fraction of
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Flavone | 2019 |
Simultaneous Relative Quantification of Various Polyglycerophospholipids with Isotope-Labeled Methylation by Nanoflow Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deuterium; Huma | 2019 |
Immunohistochemical Assessment of the Compensatory Responses in Rat Olfactory Bulbs after 6-Hydroxydopamine-Induced Lesion of the Substantia Nigra.
Topics: Adaptation, Physiological; Animals; Biomarkers; Disease Models, Animal; Gene Expression; Humans; Imm | 2019 |
Physical exercise and human adipose-derived mesenchymal stem cells ameliorate motor disturbances in a male rat model of Parkinson's disease.
Topics: Animals; Dopaminergic Neurons; Humans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem | 2019 |
Apelin-13 attenuates motor impairments and prevents the changes in synaptic plasticity-related molecules in the striatum of Parkinsonism rats.
Topics: Animals; Corpus Striatum; Intercellular Signaling Peptides and Proteins; Male; Motor Disorders; Neur | 2019 |
Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cognition; Dopamine; Female; Flavonoids; Homovanilli | 2019 |
Protective effects of β- nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2019 |
Differential enhancement of ERK, PKA and Ca
Topics: Animals; Calcium Signaling; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disea | 2019 |
Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Bromelains; Cerebral Cortex; Corpus Striatum; D | 2019 |
Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson's Disease.
Topics: Animals; Annexins; Behavior, Animal; Cell Survival; Corpus Striatum; Cymenes; Dose-Response Relation | 2020 |
Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Disulfides; Dopamine; | 2013 |
Labeling and tracking of human mesenchymal stem cells using near-infrared technology.
Topics: Animals; Cell- and Tissue-Based Therapy; Fluorescent Dyes; Humans; Male; Mesenchymal Stem Cell Trans | 2013 |
Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats.
Topics: Animals; Cell Nucleolus; Cells, Cultured; Dopaminergic Neurons; Male; Oxidopamine; Parkinson Disease | 2013 |
The majority of newly generated cells in the adult mouse substantia nigra express low levels of Doublecortin, but their proliferation is unaffected by 6-OHDA-induced nigral lesion or Minocycline-mediated inhibition of neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Dopaminergic Neurons; Doublecortin Domain Pro | 2013 |
Subthalamic hGAD65 gene therapy and striatum TH gene transfer in a Parkinson's disease rat model.
Topics: Animals; Corpus Striatum; Dependovirus; Disease Models, Animal; Gene Transfer Techniques; Genetic Th | 2013 |
AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
Topics: Animals; Dependovirus; Dopaminergic Neurons; Gene Transfer Techniques; Genetic Therapy; Locomotion; | 2013 |
A non-cholinergic neuronal loss in the pedunculopontine nucleus of toxin-evoked parkinsonian rats.
Topics: Acetylcholine; Animals; Antigens, Nuclear; Cell Death; Cholinergic Neurons; Male; Nerve Tissue Prote | 2013 |
Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Raph | 2013 |
Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease.
Topics: Animals; bcl-Associated Death Protein; Behavior, Animal; Bilirubin; Corpus Striatum; Cyclic AMP Resp | 2013 |
Targeted motor rehabilitation dissociates corticobulbar versus corticospinal dysfunction in an animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Forelimb; Male; Motor Activity; Motor Cortex; Mot | 2014 |
Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Topics: Animals; Aspartic Acid; Choline; Corpus Striatum; Creatine; Disease Models, Animal; Frontal Lobe; Fu | 2014 |
Transplantation of fetal midbrain dopamine progenitors into a rodent model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dissection; Dopaminergic Neurons; Fetus; Humans; Mesencephalon; Mic | 2013 |
Unilateral 6-OHDA lesions induce lateralised deficits in a 'skinner box' operant choice reaction time task in rats.
Topics: Animals; Choice Behavior; Conditioning, Operant; Female; Medial Forebrain Bundle; Oxidopamine; Parki | 2012 |
A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation.
Topics: Animals; Behavior, Animal; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Fa | 2012 |
Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine.
Topics: Animals; Antigens, Nuclear; Apoptosis; Caspase 3; Cytoskeleton; Dopaminergic Neurons; Enzyme Activat | 2013 |
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Dise | 2014 |
Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.
Topics: Animals; Antiparkinson Agents; Catalase; Cell Line; Gene Expression; Glutathione Peroxidase; Guanine | 2013 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Acti | 2014 |
In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
Topics: Action Potentials; alpha-Synuclein; Animals; Beta Rhythm; Humans; Male; Mice; Motor Cortex; Neurons; | 2013 |
Alterations of NMDA receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Brain; Disease Models, Animal; Male; Oxidopamine; Parkinson Disease, Sec | 2014 |
Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation.
Topics: Accidental Falls; Animals; Attention; Behavior, Animal; Cerebral Cortex; Cholinergic Neurons; Corpus | 2013 |
Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons.
Topics: Animals; Axons; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Glycine Plasma Membrane Tra | 2013 |
Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Conditioning, Operant; Dopamine Agonists; Male; Oxidop | 2013 |
Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.
Topics: Animals; Ceftriaxone; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinson Disease, Secondar | 2014 |
Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.
Topics: Acupuncture Therapy; Animals; Antiparkinson Agents; Brain Chemistry; Combined Modality Therapy; gamm | 2014 |
Comparative study of efficacy of dopaminergic neuron differentiation between embryonic stem cell and protein-based induced pluripotent stem cell.
Topics: Animals; Cell Differentiation; Cell Movement; Cells, Cultured; Dopaminergic Neurons; Embryonic Stem | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats.
Topics: Animals; Apamin; Behavior, Animal; Cognition; Corpus Striatum; Dopamine; Dose-Response Relationship, | 2014 |
Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson's disease model.
Topics: Animals; Botulinum Toxins, Type A; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Ani | 2014 |
Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Extracellular Signal-Regulat | 2014 |
An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.
Topics: Animals; Benzeneacetamides; Blood-Brain Barrier; Dibenzocycloheptenes; Humans; Microdialysis; Oxidop | 2014 |
[Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Topics: Administration, Oral; Alkaloids; Animals; Apomorphine; Catalase; Dopamine Agonists; Dopaminergic Neu | 2014 |
The effect of lentivirus-mediated PSPN genetic engineering bone marrow mesenchymal stem cells on Parkinson's disease rat model.
Topics: Animals; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Genetic Engineering; Lentivirus | 2014 |
Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.
Topics: Adrenal Medulla; alpha-Synuclein; Animals; Aromatic-L-Amino-Acid Decarboxylases; Autonomic Fibers, P | 2014 |
Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.
Topics: Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Disease Models, Animal; Gene Expression R | 2014 |
Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigen Presentation; Astroc | 2015 |
Early-onset cortico-cortical synchronization in the hemiparkinsonian rat model.
Topics: Animals; Basal Ganglia; Beta Rhythm; Cortical Synchronization; Locomotion; Male; Motor Cortex; Oxido | 2015 |
Additional noradrenergic depletion aggravates forelimb akinesia and abnormal subthalamic nucleus activity in a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Benzylamines; Disease Models, Animal; Dopamine; Forelimb; Male; Norepine | 2014 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Comb | 2014 |
Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
Topics: Animals; Brain; Dopaminergic Neurons; Encephalitis; Humans; Mitochondria; MPTP Poisoning; Neurons; O | 2015 |
Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Male; Mice; | 2015 |
Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA.
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System; Baroreflex; Biogenic Monoamines; Blood Pres | 2015 |
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.
Topics: Cell Line; Crystallography, X-Ray; Deferiprone; Humans; Iron Chelating Agents; Models, Molecular; Ne | 2015 |
Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model.
Topics: Animals; Catalase; Drug Evaluation, Preclinical; Free Radical Scavengers; Glutathione Peroxidase; Li | 2015 |
A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Gene Expression; Imidazoles; Inflam | 2015 |
Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease.
Topics: Animals; Brain; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Disease Models, Animal; | 2015 |
Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Activins; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma | 2015 |
Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset.
Topics: Animals; Behavior, Animal; Callithrix; Disease Models, Animal; Male; Motor Activity; Oxidopamine; Pa | 2015 |
Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
Topics: Animals; Apomorphine; Behavior, Animal; Blood-Brain Barrier; Carotid Arteries; Cell Count; Cell Trac | 2015 |
Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Lipopolysaccharides; Neostriatum; Neurotoxins; Oxidopamine; Parkins | 2016 |
Novel Food Supplement "CP1" Improves Motor Deficit, Cognitive Function, and Neurodegeneration in Animal Model of Parkinson's Disease.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Brain; Cholinergic Neurons; Cognition; Cyperus; Die | 2016 |
Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease.
Topics: Animals; Cell Differentiation; Cell Survival; Dopamine; Dopaminergic Neurons; Fetus; Graft Survival; | 2016 |
Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease.
Topics: Animals; Antibodies, Neutralizing; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Fe | 2016 |
Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson's disease.
Topics: Animals; Cell Membrane; Dopaminergic Neurons; Male; Mitochondria; Mitochondrial Proteins; Oxidative | 2016 |
[THYMIC HORMONES, ANTIOXIDANT ENZYMES AND NEUROGENESIS OF BULBUS OLFACTORIUS IN RATS WITH PARKINSONISM: THE EFFECT OF MELATONIN].
Topics: Animals; Antioxidants; Apomorphine; Ataxia; Catalase; Cell Count; Cell Differentiation; Dopamine Ago | 2015 |
Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Carthamus tinctorius; Cell Survival; Disease Models, Animal; Flavonoids; K | 2016 |
Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Hypokinesia; Male; Mot | 2016 |
Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Amides; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Enzy | 2016 |
Estradiol Facilitates Functional Integration of iPSC-Derived Dopaminergic Neurons into Striatal Neuronal Circuits via Activation of Integrin α5β1.
Topics: Aged; Animals; Cell Differentiation; Cells, Cultured; Corpus Striatum; Dopaminergic Neurons; Estradi | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Anim | 2016 |
NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity.
Topics: Acrylamides; Animals; Cell Survival; Cytokines; L-Lactate Dehydrogenase; Malondialdehyde; Nicotinami | 2016 |
The astrocytic response to the dopaminergic denervation of the striatum.
Topics: Animals; Astrocytes; Cell Differentiation; Cell Line; Cell Proliferation; Corpus Striatum; Denervati | 2016 |
MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease.
Topics: Animals; Brain; Disease Models, Animal; Jagged-1 Protein; Lateral Ventricles; Male; Mice, Inbred C57 | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, | 2016 |
Neuroprotective Potential of Superparamagnetic Iron Oxide Nanoparticles Along with Exposure to Electromagnetic Field in 6-OHDA Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Electromagnetic Fields; Magnetic Field Therapy; M | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induce | 2016 |
Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease.
Topics: Animals; Antigens, CD; Bromodeoxyuridine; Cell Differentiation; Cell Movement; Disease Models, Anima | 2017 |
Disrupted brain metabolic connectivity in a 6-OHDA-induced mouse model of Parkinson's disease examined using persistent homology-based analysis.
Topics: Animals; Brain; Connectome; Glucose-6-Phosphate; Male; Mice; Nerve Net; Oxidopamine; Parkinson Disea | 2016 |
A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats.
Topics: Aminoquinolines; Animals; Benzamides; Calcium; Cell Death; Drug Discovery; Dyskinesias; Endoplasmic | 2017 |
Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.
Topics: Animals; Antioxidants; Apoptosis; Berberine; Cell Survival; Disease Models, Animal; Dopaminergic Neu | 2017 |
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug | 2017 |
Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress.
Topics: Animals; Apoptosis; Astrocytes; Behavior, Animal; Caspase 3; Dioxoles; Gliosis; Lignans; Male; Malon | 2017 |
Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Topics: Acetylcarnitine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine Agonists; Dopamin | 2017 |
Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Brain; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Oxidopa | 2017 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, | 2017 |
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Diet Therapy; Disease Models, Animal; Male; Nerve Degeneration; Oxidopamin | 2008 |
[Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Estrogens; Evoked Potentials, Auditory; Femal | 2008 |
Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Topics: Animals; Basal Ganglia; Bicuculline; Brain; Cell Proliferation; Disease Models, Animal; Dose-Respons | 2008 |
Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Genistein; Male; Motor Acti | 2009 |
Effects of neostriatal 6-OHDA lesion on performance in a rat sequential reaction time task.
Topics: Animals; Conditioning, Operant; Dopamine; Male; Neostriatum; Oxidopamine; Parkinson Disease, Seconda | 2008 |
Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Dextroamphetamine; Docosahexaenoic Acid | 2008 |
Arterial baroreflex dysfunction fails to mimic Parkinson's disease in rats.
Topics: Animals; Baroreflex; Behavior, Animal; Blood Pressure; Catalepsy; Corpus Striatum; Denervation; Dopa | 2008 |
Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats.
Topics: Amino Acid Transport System y+; Animals; Blotting, Western; Corpus Striatum; Disease Models, Animal; | 2008 |
1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Topics: Animals; Blotting, Western; Calcitriol; Corpus Striatum; Disease Models, Animal; Gene Expression; Gl | 2009 |
Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Benzamidines; Disease Models | 2009 |
Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, | 2008 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopami | 2008 |
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Mo | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents | 2009 |
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Dyskinesias; Extracellular Signal-Regulated MAP Ki | 2009 |
Mobilization of neural stem cells and generation of new neurons in 6-OHDA-lesioned rats by intracerebroventricular infusion of liver growth factor.
Topics: Animals; Bilirubin; Cell Movement; Cell Proliferation; Cerebral Ventricles; Corpus Striatum; Doublec | 2009 |
Electrophysiological effects of neurotensin on globus pallidus neurons of 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Antiparkinson Agents; Central Nervous System Agents; Globus Pallidus; Im | 2009 |
Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dop | 2009 |
NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cell Count; Disease | 2009 |
Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine.
Topics: Analysis of Variance; Animals; Autophagy; Cathepsin L; Cathepsins; Cell Count; Cell Cycle; Cell Deat | 2009 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine a | 2009 |
The firing activity of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Cell Count; Male; Oxidopamine; P | 2009 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Str | 2009 |
Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters.
Topics: Animals; Cell Survival; Dopamine; Embryonic Stem Cells; Female; Mesencephalon; Neurons; Oxidopamine; | 2009 |
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Electrophysiology; | 2009 |
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Male; Microglia; Neurons; Oxidopamine; Parkinson Disease, | 2009 |
[Study on the mechanism of electroacupuncture scalp point penetration therapy in action on apoptosis in the Parkinson's disease rat model].
Topics: Acupuncture Points; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Electroacupuncture; Femal | 2009 |
Bilateral high frequency stimulation of the subthalamic nucleus normalizes COX activity in the substantia nigra of Parkinsonian rats.
Topics: Animals; Cell Count; Corpus Striatum; Deep Brain Stimulation; Dopamine; Electrodes, Implanted; Elect | 2009 |
Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats.
Topics: Animals; Male; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley | 2009 |
Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons.
Topics: Animals; Behavior, Animal; Carrier Proteins; Cytokines; Disease Models, Animal; Dopamine; Dose-Respo | 2009 |
Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Topics: Adrenergic Agents; Animals; Dependovirus; Dopamine; Doxycycline; Female; Gene Expression; Gene Trans | 2009 |
Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Glial Cell Line-Derived Neurotrophic Fac | 2009 |
Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.
Topics: Analysis of Variance; Animals; Axons; Cell Count; Cell Transplantation; Corpus Striatum; Dopamine; F | 2009 |
Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.
Topics: Animals; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Ginsenosides; Insulin-Like G | 2009 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Elec | 2009 |
Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Analysis of Variance; Animals; Autoradiography; Brain; Dopamine; Image Processing, Computer-Assisted | 2010 |
Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Locus Coeruleus; | 2010 |
Exercise exerts neuroprotective effects on Parkinson's disease model of rats.
Topics: Amphetamine; Animals; Ascorbic Acid; Behavior, Animal; Brain-Derived Neurotrophic Factor; Bromodeoxy | 2010 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal | 2010 |
Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
Topics: Adenosine Triphosphate; Animals; Behavior, Animal; Cell Line; Cell Line, Tumor; Disease Models, Anim | 2010 |
Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Male; Mice; Needles; Oxidopamine | 2010 |
Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Glial Cell | 2009 |
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Extracellular Spac | 2010 |
Neuroprotective effects of herbal ethanol extracts from Gynostemma pentaphyllum in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Cell Death; Disease Models, Animal; Ethanol; Gynostemma; Male; Neurons; Neuroprotective Age | 2010 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; | 2010 |
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Depre | 2010 |
Long term exposure to norharman exacerbates 6-hydroxydopamine-induced parkinsonism: possible involvement of L-type Ca2+ channels.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Calcium Channel Blockers; Calcium Channels, | 2010 |
Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats.
Topics: Animals; Aspartic Acid; Blotting, Western; Chromatography, High Pressure Liquid; Corpus Striatum; Do | 2010 |
[Biochemical changes in striatum of Parkinson's disease rat model observed by modified proton magnetic resonance spectroscopy].
Topics: Animals; Corpus Striatum; Female; Magnetic Resonance Spectroscopy; Male; Oxidopamine; Parkinson Dise | 2010 |
Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Cysteine Proteinase I | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transp | 2010 |
Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes.
Topics: Amino Acid Sequence; Animals; Calcium; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional | 2010 |
Automated quantitative gait analysis in animal models of movement disorders.
Topics: Animals; Automation; Brain; Disease Models, Animal; Female; Gait; Huntington Disease; Intracranial T | 2010 |
Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Chromatography, High Pressure Liquid; Dietary Fats | 2010 |
Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats.
Topics: Algorithms; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Blotting, Wes | 2010 |
Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons.
Topics: Animals; Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Cells, Cultured; Disease Models, | 2011 |
[The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Female; Ginsenosides; Neuroprotective Agents; | 2008 |
Neuroprotective properties of mildronate, a small molecule, in a rat model of Parkinson's disease.
Topics: Animals; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Glial Fibrillary Acidic Protein; Mal | 2010 |
[The neuroprotective effects of lesion and high frequency stimulation of the subthalamic nucleus on the substantia nigra neurons].
Topics: Animals; bcl-2-Associated X Protein; Electric Stimulation; Male; Neurons; Oxidopamine; Parkinson Dis | 2009 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition D | 2011 |
[Autophagy is involved in 6-OHDA-induced dopaminergic cell death].
Topics: Animals; Autophagy; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Male; Microtubule-Asso | 2010 |
Modulation of excessive neuronal activity by fibroblasts: potential use in treatment of Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Fibroblasts; Motor Activity; Neurons; Oxidopamine; Parkinson Dise | 2010 |
Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation.
Topics: Animals; Behavior, Animal; Bone Marrow Cells; Bone Marrow Transplantation; Cerebral Cortex; Cyclic A | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Ch | 2011 |
Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.
Topics: Animals; bcl-2-Associated X Protein; Binding, Competitive; Cerebellar Diseases; Cerebellum; Cyclic A | 2011 |
Tongue force and timing deficits in a rat model of Parkinson disease.
Topics: Animals; Basal Ganglia; Deglutition Disorders; Disease Models, Animal; Male; Medial Forebrain Bundle | 2011 |
Dynamic changes of striatal dopamine D2 receptor binding at later stages after unilateral lesions of the medial forebrain bundle in Parkinsonian rat models.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine Plasma Membrane Transport Protein | 2011 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; | 2011 |
ES cell-derived renewable and functional midbrain dopaminergic progenitors.
Topics: Animals; Cell Differentiation; Cell Line; Cell Proliferation; Dopamine; Embryonic Stem Cells; Fibrob | 2011 |
Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum.
Topics: Algorithms; Animals; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Electric Stimulat | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Cortical stimulation evokes abnormal responses in the dopamine-depleted rat basal ganglia.
Topics: Action Potentials; Animals; Basal Ganglia; Cerebral Cortex; Dihydroxyphenylalanine; Male; Motor Acti | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; E | 2011 |
Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease.
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Line; Cells, Cultured; Cytochromes c; Disease Models, | 2011 |
[High-frequency electro-acupuncture stimulation modulates intracerebral γ-aminobutyric acid content in rat model of Parkinson's disease].
Topics: Acupuncture Therapy; Animals; Brain; Electroacupuncture; gamma-Aminobutyric Acid; Male; Motor Cortex | 2011 |
[Effects and mechanism of low frequency stimulation of pedunculopontine nucleus on spontaneous discharges of ventrolateral thalamic nucleus in rats].
Topics: Acetylcholine; Action Potentials; Animals; Cholinergic Fibers; Electric Stimulation; Male; Oxidopami | 2011 |
The effect of striatal dopaminergic grafts on the neuronal activity in the substantia nigra pars reticulata and subthalamic nucleus in hemiparkinsonian rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Female; Motor Activity; Neurons; Oxidopamine; | 2011 |
Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease.
Topics: Acetylcholine; Animals; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Disease M | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; D | 2011 |
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5 | 2012 |
Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism.
Topics: Animals; Benzylamines; Electrophysiological Phenomena; Extracellular Space; Fenclonine; Globus Palli | 2012 |
The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Up | 2012 |
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Medial Forebrain Bundle; Mice; Mic | 2012 |
Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.
Topics: Animals; Cardiovascular Agents; Corpus Striatum; Disease Models, Animal; Glial Cell Line-Derived Neu | 2011 |
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamin | 2012 |
Frequency selectivity and dopamine-dependence of plasticity at glutamatergic synapses in the subthalamic nucleus.
Topics: Animals; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Glutamic Acid; Male; Ne | 2012 |
RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits.
Topics: Animals; Cannabinoid Receptor Modulators; Corpus Striatum; Dopamine; Long-Term Synaptic Depression; | 2012 |
Effect of DHEA on recovery of muscle atrophy induced by Parkinson's disease.
Topics: Animals; Corpus Striatum; Dehydroepiandrosterone; Extracellular Signal-Regulated MAP Kinases; Male; | 2011 |
A 6-hydroxydopamine in vivo model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Oxidopamine; Parkinson Disease, Secondary; Ra | 2012 |
Effect of cabergoline on increase of several ER stress-related molecules in 6-OHDA-lesioned mice.
Topics: Animals; Antiparkinson Agents; Cabergoline; Caspase 12; Endoplasmic Reticulum; Endoplasmic Reticulum | 2013 |
Functional neuroimaging of the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Functional Neuroimaging; Male; Motor Activity; Neurons; Oxidopamin | 2012 |
Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Medial | 2012 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Bensera | 2012 |
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino | 2012 |
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cells; Dopaminergic Neurons; Inflammation; M | 2012 |
2-Benzazepine nitrones protect dopaminergic neurons against 6-hydroxydopamine-induced oxidative toxicity.
Topics: Animals; Benzazepines; Brain; Cell Count; Cells, Cultured; Cholinesterase Inhibitors; Cyclic N-Oxide | 2012 |
Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-X(L).
Topics: Animals; bcl-X Protein; Behavior, Animal; Cell Line; Cell Survival; Cells, Cultured; Central Nervous | 2012 |
Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Curcumin; Disease Models, Animal; Dopaminergic Neurons; Female; Iron; Iron Chelating Agents | 2012 |
Exercise partly reverses the effect of maternal separation on hippocampal proteins in 6-hydroxydopamine-lesioned rat brain.
Topics: Animals; Cytoskeletal Proteins; Disease Models, Animal; Energy Metabolism; Hippocampus; Male; Matern | 2013 |
7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Enzyme Inh | 2012 |
Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.
Topics: Animals; Behavior, Animal; Brain; Dopamine; Exenatide; Male; Motor Activity; Neurons; Norepinephrine | 2012 |
Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopaminergic Neurons; Fibroblast Growth Factors; Male; Motor Activity; Ner | 2012 |
Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.
Topics: Animals; Antipsychotic Agents; Beta Rhythm; Deep Brain Stimulation; Forelimb; Hypokinesia; Male; Oxi | 2013 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therap | 2012 |
Comparison of 6-hydroxydopamine lesions of the substantia nigra and the medial forebrain bundle on a lateralised choice reaction time task in mice.
Topics: Animals; Choice Behavior; Conditioning, Operant; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C | 2013 |
Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.
Topics: Animals; Beta Rhythm; Deep Brain Stimulation; Forelimb; Hypokinesia; Male; Motor Activity; Oxidopami | 2013 |
Effective deep brain stimulation suppresses low-frequency network oscillations in the basal ganglia by regularizing neural firing patterns.
Topics: Action Potentials; Animals; Basal Ganglia; Behavior, Animal; Deep Brain Stimulation; Female; Motor A | 2012 |
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Im | 2012 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agonists; Male; Maz | 2002 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationsh | 2002 |
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.
Topics: Amino Acids; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycli | 2002 |
Comparison of fresh and cryopreserved porcine ventral mesencephalon cells transplanted in A rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cell Culture Techniques; Corpus Striatum; Cryopreserva | 2002 |
Efficacy of elevated body swing test in the early model of Parkinson's disease in rat.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Male; Neostriatum; Oxidopamine; Parkin | 2002 |
Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cell Death; Corpus Striatum; Disease Models, Anima | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopam | 2002 |
Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT.
Topics: Animals; Cell Count; Cocaine; Dopamine Plasma Membrane Transport Proteins; Magnetic Resonance Imagin | 2002 |
Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Cardiotonic Agents; Convection; Corpus Striatum; Disease Models, Animal; | 2003 |
Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Blotting, Western; Carrier Proteins; Caspases; CCAAT-Enhancer-Binding P | 2003 |
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzimidazoles; Dopamin | 2003 |
Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
Topics: Acupuncture Therapy; Animals; Apomorphine; Behavior, Animal; Cell Count; Cell Survival; Corpus Stria | 2003 |
Protective effect of GSH on PD model induced by 6-OHDA in vitro.
Topics: Animals; Glutathione; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; R | 2002 |
Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Casts, Surgical; Corpus Stri | 2003 |
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Cell Line; Gene Expression; Genetic | 2003 |
Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.
Topics: Animals; Cell Transplantation; Female; Immunohistochemistry; Mesencephalon; Neurons; Oxidopamine; Pa | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug | 2003 |
Gene expression of glutamate receptors GluR1 and NR1 is differentially modulated in striatal neurons in rats after 6-hydroxydopamine lesion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Female; Fluorescent Antibody Technique; Gene Expre | 2003 |
Neural stem cells. Biological features and therapeutic potential in Parkinson's disease.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Immunohistochemistry; Mice; Mice, Inbred Strains; | 2003 |
Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain.
Topics: Animals; Apoptosis; Blood Pressure; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; | 2003 |
Dopaminergic trophism after intrastriatal injection of lentivirus-transferred GDNF in Parkinson rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Cerebral Cortex; Corpus Striatum; Disease Models, | 2003 |
Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences.
Topics: Adenosine; Animals; Behavior, Animal; Brain Chemistry; Catalase; Dopamine; Glutathione; Glutathione | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkin | 2003 |
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dose | 2004 |
Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease M | 2004 |
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Caffeine; Conditioning, Operant; Dopamine; Dopami | 2004 |
[Therapeutic study of autologous Schwann cells' bridge graft into the brain of hemiparkinsonian monkey].
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Dopamine; Haplorhini; Microscopy, Fluores | 2004 |
Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Topics: Animals; Apomorphine; Autoradiography; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neostriat | 2004 |
Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Dyskinesias; Immunohistochemistry; Levo | 2004 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neost | 2004 |
Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Female; Gene E | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Dise | 2005 |
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Topics: Animals; Appetitive Behavior; Callithrix; Choice Behavior; Dependovirus; Disease Models, Animal; Dop | 2005 |
Grafts of adult subependymal zone neuronal progenitor cells rescue hemiparkinsonian behavioral decline.
Topics: Animals; Behavior, Animal; Bromodeoxyuridine; Cell Count; Cell Differentiation; Cell Movement; Cells | 2005 |
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membra | 2005 |
Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats.
Topics: Adrenergic Agents; Animals; Behavioral Research; Dopamine; Exploratory Behavior; Functional Laterali | 2005 |
Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dose-Response | 2005 |
Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Cell Co | 2005 |
Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
Topics: Amphetamine; Analysis of Variance; Animals; Blotting, Western; Cell Count; Cell Line; Cloning, Molec | 2005 |
Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cell Count; Dynorphins; Enkephalins; Globus Pa | 2005 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Dopamine; Immunohistochemistry; Inject | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dep | 2006 |
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Topics: Adrenergic Agents; Aldehydes; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; CD11b A | 2005 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, An | 2006 |
Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
Topics: Animals; Basal Ganglia; Cerebral Cortex; Denervation; Dopamine Uptake Inhibitors; Electron Transport | 2005 |
Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Astrocytes; Cell Count; Cell Transplantation; Cells, Cultured; Central Nervous | 2005 |
Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Bilirubin; Corpus Striatum; Dopamine; Female; Growth Substances; Microglia; Motor Activity; | 2006 |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; L | 2006 |
Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease.
Topics: Animals; Cell Survival; Cell Transplantation; Cells, Cultured; Dopamine; Erythropoietin; Immunohisto | 2006 |
Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain-Derived Neurotrophic Factor; Densitometry; Dopamine Agonists; Functional | 2006 |
Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug | 2006 |
Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Embryo, Ma | 2006 |
Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
Topics: Animals; Antioxidants; Behavior, Animal; Catalase; Dopamine; Glutathione; Glutathione Reductase; Glu | 2006 |
L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases.
Topics: Animals; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopami | 2006 |
A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.
Topics: Animals; Apomorphine; Blood-Brain Barrier; Brain Chemistry; Cell Line, Tumor; Gene Products, tat; Hu | 2006 |
On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
Topics: Animals; Motor Activity; Neuronal Plasticity; Oxidopamine; Parkinson Disease, Secondary; Rats; Subst | 2006 |
Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease.
Topics: Animals; Brain; Catalase; Delphinium; Disease Models, Animal; Dopamine; Dose-Response Relationship, | 2006 |
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Biotransformation; Catecholamines; Foreli | 2006 |
Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats.
Topics: Animals; Apomorphine; Corpus Striatum; Dopamine; Genetic Therapy; Genetic Vectors; Glial Cell Line-D | 2006 |
Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum.
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dopamine; Dopa | 2006 |
Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model.
Topics: Animals; Data Interpretation, Statistical; Electrophysiology; Excitatory Amino Acid Agonists; Iboten | 2006 |
Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Blotting, Western; Calcium-Calmodulin | 2006 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line--studies in vitro and after intracerebral grafting in vivo.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Differentiation; | 2007 |
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
Topics: Animals; Basal Ganglia; Behavior, Animal; Cell Death; Cytochromes c; Disease Models, Animal; Immunoh | 2007 |
Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Bone Marrow Transplantation; Cells, Cultured; Disease Models, Animal; Dopamine | 2007 |
Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Behavior, Animal; Cell Count; Densitometry; Dopamine; | 2007 |
Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat.
Topics: Animals; Corpus Striatum; Disease Progression; Dopamine; Electrophysiology; Globus Pallidus; Male; M | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavi | 2007 |
Dopaminergic differentiation of grafted GFP transgenic neuroepithelial stem cells in the brain of a rat model of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Brain; Cell Differentiation; Cell Survival; Cell Transplanta | 2007 |
Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine | 2007 |
Spatial deficits in a mouse model of Parkinson disease.
Topics: Analysis of Variance; Animals; Animals, Outbred Strains; Avoidance Learning; Behavior, Animal; Cogni | 2007 |
Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Topics: Animals; Apomorphine; Cell Survival; Dopamine; Dopamine Agonists; Immunohistochemistry; Male; Neostr | 2007 |
The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
Topics: Animals; Apomorphine; Blotting, Western; Corticotropin-Releasing Hormone; Data Interpretation, Stati | 2007 |
A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Cell Transplantation; Dopamine; Dopamine Agonists | 2007 |
[Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson's disease].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catechols; Chromatography, High Pressure Liquid; C | 2007 |
A golgi analysis of cortical pyramidal cells in the unilateral parkinson rat: absence of change in the affected hemisphere vs hypertrophy in the intact hemisphere.
Topics: Animals; Apomorphine; Cerebral Cortex; Dendrites; Dendritic Spines; Dextroamphetamine; Female; Forel | 2007 |
Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
Topics: Absorbable Implants; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; | 2007 |
Sensory (nociceptive) stimulation evokes Fos expression in the subthalamus of hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Gene Expression Regulation; Male; Neurons; Oncogene Pro | 2008 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzox | 2007 |
Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity.
Topics: Animals; Cell Line; Cytoprotection; Dopamine; Dopamine Agents; Levodopa; Metallothionein; Mice; Mice | 2007 |
Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Differentiation; Cells, Cultured; Central Nervous System Stimulants; Data | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Solid lipid nanoparticles as delivery systems for bromocriptine.
Topics: Absorptiometry, Photon; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Chromatograp | 2008 |
Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secon | 2008 |
Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease.
Topics: Acetylcysteine; Adrenergic Agents; Animals; Apoptosis; Caspase 3; Cell Line; Disease Models, Animal; | 2008 |
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
Topics: Animals; Autoradiography; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonist | 2008 |
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Topics: Animals; Antimetabolites; Behavior, Animal; Bromodeoxyuridine; Cells, Cultured; DNA Primers; Dopamin | 2008 |
Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Bridged-Ring Compounds; Disease Models | 2008 |
Increasing extracellular potassium results in subthalamic neuron activity resembling that seen in a 6-hydroxydopamine lesion.
Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dose-Res | 2008 |
Postmenopausal effects of intrastriatal estrogen on catalepsy and pallidal electroencephalogram in an animal model of Parkinson's disease.
Topics: Animals; Catalepsy; Electroencephalography; Estrogens; Female; Globus Pallidus; Muscle, Skeletal; Ne | 2008 |
Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Topics: Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Male; Oxidopamine; Parkinso | 1982 |
Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Topics: Age Factors; Animals; Antipsychotic Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, | 1984 |
Neural-targeted gene therapy for rodent and primate hemiparkinsonism.
Topics: Animals; Brain Tissue Transplantation; Gene Expression; Genetic Therapy; Macaca mulatta; Oxidopamine | 1994 |
Identification of NO-producing and -receptive cells in mesencephalic transplants in a rat model of Parkinson's disease: a study using NADPH-d enzyme- and NOSc/cGMP immunocytochemistry.
Topics: Amino Acid Oxidoreductases; Animals; Brain Tissue Transplantation; Cyclic GMP; Disease Models, Anima | 1994 |
Impairments and compensatory adjustments in spontaneous movement after unilateral dopamine depletion in rats.
Topics: Animals; Behavior, Animal; Brain Chemistry; Dopamine; Feeding Behavior; Female; Functional Lateralit | 1995 |
Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism.
Topics: Animals; Behavior, Animal; Feasibility Studies; Male; Movement; Oxidopamine; Parkinson Disease, Seco | 1995 |
L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.
Topics: Animals; Dopamine; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Prefronta | 1995 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Differentiation of motor inactivation from movement asymmetry effects in an animal model of hemi-parkinsonism.
Topics: Animals; Corpus Striatum; Dopamine; Male; Motor Activity; Movement; Osmolar Concentration; Oxidopami | 1994 |
Reversal of mitochondrial damage in a rat model of Parkinson's disease by a neurotrophic peptide (MPF analogue).
Topics: Amino Acid Sequence; Animals; Male; Maturation-Promoting Factor; Microscopy, Electron; Mitochondria; | 1994 |
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.
Topics: Adenoviruses, Human; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Brain; Corpus Stria | 1994 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebra | 1994 |
A model three-dimensional culture system for mammalian dopaminergic precursor cells: application for functional intracerebral transplantation.
Topics: Animals; Brain Tissue Transplantation; Bucladesine; Cell Aggregation; Cell Differentiation; Cells, C | 1993 |
Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain.
Topics: Amphetamine; Animals; Behavior, Animal; Dopamine; Drug Implants; Interleukin-1; Male; Neurons; Oxido | 1994 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity | 1994 |
Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Cell Transplantation; Dopamine; Female; Fetal Ti | 1994 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Domina | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combination | 1994 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervatio | 1994 |
Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Benzazepines; Do | 1994 |
Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism.
Topics: Animals; Apomorphine; Capsules; Dopamine; Immunohistochemistry; Lactic Acid; Male; Microspheres; Neo | 1994 |
Functional effects of transplanted human fetal ventral mesencephalic brain tissue from spontaneous abortions into a rodent model of Parkinson's disease.
Topics: Abortion, Spontaneous; Amphetamine; Animals; Biomarkers; Brain Tissue Transplantation; Female; Fetal | 1994 |
Brain-derived neurotrophic factor enhances striatal neuropeptide expression in both the intact and the dopamine-depleted rat striatum.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Enkephalins; Female; Gene Exp | 1994 |
L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Levodopa; Male; Neurons; Oxidopa | 1994 |
Intracerebral grafting of genetically modified cells. Applications to a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Corpus Striatum; Fibroblasts; Genetic Engineering; Oxidopamine; Parkinson Dise | 1993 |
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Ac | 1993 |
Long-term correction of rat model of Parkinson's disease by gene therapy.
Topics: Animals; Animals, Newborn; Apomorphine; Brain; Cells, Cultured; Dopamine; Drug Carriers; Female; Gen | 1993 |
Midbrain 6-hydroxydopamine lesions modulate blink reflex excitability.
Topics: Amphetamine; Animals; Basal Ganglia; Blinking; Electric Stimulation; Electromyography; Habituation, | 1993 |
Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Benzazepines; Cerebral Ventricles; Corpus Striat | 1993 |
Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids.
Topics: Amino Acids; Animals; Levodopa; Male; Neostriatum; Neural Pathways; Oxidopamine; Parkinson Disease, | 1993 |
Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1993 |
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
Topics: Animals; Deferoxamine; Dominance, Cerebral; Ferritins; Free Radicals; Humans; Hydrogen Peroxide; Hyd | 1993 |
Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Topics: Animals; Brain; Corpus Striatum; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Dis | 1993 |
Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Male; Mesencephalo | 1995 |
Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: survival and function of graft.
Topics: Animals; Catecholamines; Cells, Cultured; Corpus Striatum; Ganglia, Sympathetic; Graft Survival; Mal | 1995 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agon | 1995 |
HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height.
Topics: Animals; Appetitive Behavior; Brain Mapping; Corpus Striatum; Dominance, Cerebral; Dopamine; Female; | 1996 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo.
Topics: Acetylcholine; Adenosine; Animals; Corpus Striatum; Drug Combinations; GABA Antagonists; Male; Musci | 1996 |
Dopaminergic transplants alter in vivo activity of tryptophan hydroxylase in the striatum in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; | 1996 |
Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Caudate Nucleus; Corpus Striatum; Dizocilpine Maleate; Dopami | 1996 |
GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Fetal Tissue Transplantation; Gli | 1996 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Ce | 1996 |
Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study.
Topics: Animals; Calcium; Copper; Image Processing, Computer-Assisted; Iron; Magnesium; Male; Oxidopamine; P | 1996 |
Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Drug Administration Schedule; Dr | 1996 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid | 1995 |
Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antibody Specificity; Behavior, Animal; Cell Death; Disease Models, Animal; Do | 1996 |
Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Dopamine Agents; Fem | 1996 |
An explanation for reflex blink hyperexcitability in Parkinson's disease. I. Superior colliculus.
Topics: Animals; Blinking; Electric Stimulation; GABA Agonists; Microinjections; Muscimol; Oxidopamine; Park | 1996 |
Dynamic regulation of striatal dopaminergic grafts during locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Extracellu | 1996 |
Impairments and compensation in mouth and limb use in free feeding after unilateral dopamine depletions in a rat analog of human Parkinson's disease.
Topics: Animals; Brain Chemistry; Dopamine; Extremities; Feeding Behavior; Female; Food; Head Movements; Mou | 1997 |
Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test.
Topics: Amphetamine; Animals; Apomorphine; Automation; Brain Tissue Transplantation; Female; Fetal Tissue Tr | 1997 |
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
Topics: Adenylyl Cyclases; Animals; Benzazepines; Binding, Competitive; Cell Membrane; Corpus Striatum; Dopa | 1997 |
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agonists; Drug Interact | 1997 |
Effects of graft pooling of foetal rat and mouse tissue and immunosuppression in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cyclosporine; Female; Fetal Tissue Transpla | 1997 |
Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice.
Topics: Animals; Corpus Striatum; Cyclosporine; Disease Models, Animal; Dopamine; Glucocorticoids; Hydrocort | 1997 |
Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Corpus Striatum; Dopamine; Glial C | 1998 |
Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats.
Topics: Animals; Cells, Cultured; Corpus Striatum; Dopamine; Functional Laterality; Male; Neurons; Oxidopami | 1997 |
Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bone Morphogenetic Proteins; Corpus Striatum; Dopamine; Gro | 1997 |
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
Topics: Animals; Dependovirus; Disease Models, Animal; Gene Expression; Genetic Therapy; Genetic Vectors; Gl | 1997 |
Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Astrocytes; Brain Tissue Transplantation; Cell Count; Cell Differentiation; Ce | 1997 |
Intracerebral transplantation of testis-derived sertoli cells promotes functional recovery in female rats with 6-hydroxydopamine-induced hemiparkinsonism.
Topics: Animals; Apomorphine; Corpus Striatum; Dominance, Cerebral; Female; Graft Enhancement, Immunologic; | 1997 |
The ground reaction forces of postural adjustments during skilled reaching in unilateral dopamine-depleted hemiparkinson rats.
Topics: Adaptation, Physiological; Animals; Biomechanical Phenomena; Dopamine; Female; Forelimb; Motor Skill | 1997 |
An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism.
Topics: Animals; Apomorphine; Automation; Brain; Disease Models, Animal; Equipment Design; Female; Motor Act | 1997 |
Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
Topics: Amphetamine; Animals; Apomorphine; Conditioning, Operant; Corpus Striatum; Discrimination Learning; | 1998 |
Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Denervation; Female; Glial Cell Line-Derived Neurotrophic Factor; Immunohi | 1998 |
Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates.
Topics: Amphetamine; Animals; Behavior, Animal; Carotid Body; Corpus Striatum; Disease Models, Animal; Dopam | 1998 |
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Agon | 1998 |
Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Do | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Prot | 1998 |
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagoni | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease | 1998 |
Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Bovine papillomavirus 1; Cattle; Disease Models, Anim | 1998 |
Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor.
Topics: Adrenergic Agents; Adrenergic Fibers; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell | 1998 |
Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Combined Modality Therapy; Cytokines; Disease Models, Animal; Dopamine; Female; Fetal Tissu | 1998 |
Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats.
Topics: Adrenal Glands; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Astrocytes; Behavior, Animal | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, An | 1998 |
MK-801 does not enhance dopaminergic cell survival in embryonic nigral grafts.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Dizocilpine Maleate; Female; Fetal Tissue Tran | 1998 |
Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Mo | 1998 |
Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice.
Topics: Animals; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; F | 1998 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
[Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dextroamphetamine; Dominance, Cerebral; Dop | 1998 |
Dopaminergic graft-induced long-term recovery of complex sensorimotor behaviors in a rat model of Parkinson's disease.
Topics: Animals; Brain Mapping; Brain Tissue Transplantation; Dopamine; Female; Fetal Tissue Transplantation | 1998 |
N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Corpus Striatum; | 1998 |
Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons.
Topics: Animals; Antimetabolites; Behavior, Animal; Brain Tissue Transplantation; Bromodeoxyuridine; Corpus | 1998 |
Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Lidocaine; Male; Motor Activity; Organ Spe | 1998 |
Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Brain Tissue Transplantation; Corpus Stria | 1998 |
[Simultaneous transplantation of fetal mesencephalic cells to the striatum and globus pallidus of rats with lesions induced by 6-hydroxydopamine].
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Fetal Tissue Transplant | 1998 |
[Expression of foreign tyrosine hydroxylase gene in the rat model of Parkinson's disease].
Topics: Animals; Apomorphine; Gene Expression; Genetic Therapy; Oxidopamine; Parkinson Disease, Secondary; R | 1997 |
6-OHDA denervation substantially decreases DCC mRNA levels in rat substantia nigra compacta.
Topics: Animals; Antisense Elements (Genetics); Behavior, Animal; Cell Adhesion Molecules; Cell Adhesion Mol | 1998 |
Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspase | 1999 |
In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats.
Topics: Acetylcholine; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Amino Acid Ago | 1999 |
Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism.
Topics: Animals; Astrocytes; beta-Galactosidase; Gene Expression; Gene Transfer Techniques; Genetic Therapy; | 1998 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agent | 1999 |
Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Cell Count; Dopamine; Dopamine Agonists; Female; | 1999 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopam | 1999 |
Kir6.2 oligoantisense administered into the globus pallidus reduces apomorphine-induced turning in 6-OHDA hemiparkinsonian rats.
Topics: Animals; Apomorphine; Globus Pallidus; Male; Motor Activity; Neurons; Oligodeoxyribonucleotides, Ant | 1999 |
Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions.
Topics: Adaptation, Physiological; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal | 1999 |
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Atrophy; Body Weight; Cerebral Ventricles; Corpus Str | 1999 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
Systematic expression of immediate early genes and intensive astrocyte activation induced by intrastriatal ferrous iron injection.
Topics: Animals; Astrocytes; Behavior, Animal; Coloring Agents; Corpus Striatum; Dopamine; Ferrocyanides; Fe | 1999 |
The toxicity of 6-hydroxydopamine on PC12 and P19 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurintricarboxylic Acid; Biological Transport; Bisbenzimi | 1999 |
Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats.
Topics: Animals; Functional Laterality; Gene Expression Regulation; Immunohistochemistry; Male; Oxidopamine; | 1999 |
[Intracerebral transplantation of genetically modified cells for Parkinson's disease].
Topics: 3T3 Cells; Animals; Corpus Striatum; Fetal Tissue Transplantation; Gene Transfer Techniques; Genetic | 1997 |
[Intracerebral grafting of ex vivo transgene muscle cells in rat model of parkinsonism].
Topics: Animals; Animals, Newborn; Cell Transplantation; Cells, Cultured; Corpus Striatum; Gene Transfer Tec | 1997 |
Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamines; Animals; Chromatography, H | 1999 |
Ground reaction forces in locomoting hemi-parkinsonian rats: a definitive test for impairments and compensations.
Topics: Adaptation, Physiological; Animals; Corpus Striatum; Dopamine; Extremities; Female; Gait; Gravitatio | 1999 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Topics: Animals; Crystallography, X-Ray; Dopamine Agents; Lactams; Male; Models, Molecular; Molecular Mimicr | 1999 |
Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat.
Topics: Animals; Attention; Female; Head; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Posture | 1999 |
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene.
Topics: Animals; Cell Transplantation; Genetic Therapy; Glial Fibrillary Acidic Protein; Glioma; Humans; Mal | 1999 |
Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease.
Topics: Amphetamines; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedu | 1999 |
Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid Antag | 1999 |
Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Topics: Animals; Cytomegalovirus; Dependovirus; Dopamine; Genes, Reporter; Genetic Therapy; Genetic Vectors; | 1999 |
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Membrane; Corpus Striatum; Disease Models, Animal; Levodopa; Mal | 2000 |
Relative sparing of calretinin containing neurons in the substantia nigra of 6-OHDA treated rat parkinsonian model.
Topics: Animals; Calbindin 2; Cell Survival; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; | 2000 |
Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 1999 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Mo | 2000 |
Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain.
Topics: Aging; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Nerv | 2000 |
6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra.
Topics: Animals; Apoptosis; Cell Nucleus; Disease Models, Animal; Dopamine; Immunohistochemistry; In Situ Ni | 2000 |
Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats.
Topics: Action Potentials; Animals; Carrier Proteins; Corpus Striatum; Denervation; Dopamine Plasma Membrane | 2000 |
The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function.
Topics: Animals; Attention; Brain Mapping; Callithrix; Caudate Nucleus; Discrimination Learning; Dopamine; F | 2000 |
Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Count; Cell Line; Corpus Striatum; Disease Models, Animal; Dopamine; Fema | 2000 |
Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Central Nervous System Stimula | 2000 |
Imaging the rat brain on a 1.5 T clinical MR-scanner.
Topics: Animals; Artifacts; Blood-Brain Barrier; Brain; Brain Tissue Transplantation; Female; Huntington Dis | 2000 |
A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; CD8-Positive T-Lymphocytes; Complement Activation; Disease Models, Anima | 2000 |
Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Topics: Animals; Benzimidazoles; Electrophysiology; Excitatory Amino Acid Antagonists; Hydantoins; Hydrogen | 2000 |
Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats.
Topics: Adenoviridae; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Cell | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agon | 2000 |
Differential expression of neurotrophin and neurotrophin receptor mRNAs in and adjacent to fetal midbrain grafts implanted into the dopamine-denervated striatum.
Topics: Animals; Brain Tissue Transplantation; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus St | 2000 |
Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Dopamine; Genes, Reporter; Genetic Therapy; Genet | 2000 |
Systemic treatment with GM1 ganglioside improves survival and function of cryopreserved embryonic midbrain grafted to the 6-hydroxydopamine-lesioned rat striatum.
Topics: Animals; Brain Tissue Transplantation; Cell Count; Cell Survival; Corpus Striatum; Cryopreservation; | 2000 |
Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease.
Topics: Animals; Cell Count; Corpus Striatum; Delayed-Action Preparations; Disease Models, Animal; Drug Impl | 2000 |
Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
Topics: Animals; Apomorphine; Benzazepines; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamin | 2000 |
Real-time dynamics of dopamine released from neuronal transplants in experimental Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Electr | 2000 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Diz | 2000 |
The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Topics: Animals; Calbindin 2; Calcium-Binding Proteins; Cell Count; Corpus Striatum; Disease Models, Animal; | 2000 |
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
Topics: Animals; Antibodies; Apoptosis; Behavior, Animal; Body Weight; Denervation; Dopamine; Exploratory Be | 2000 |
Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Chromatography, Gel; Cysteine; Freeze Dryin | 2000 |
Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study.
Topics: Animals; Body Temperature; Corpus Striatum; Disease Models, Animal; Heart Rate; Locomotion; Male; Ox | 2000 |
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Cyclic AMP; Disease | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Syne | 2000 |
Akinesia and postural abnormality after unilateral dopamine depletion.
Topics: Animals; Behavior, Animal; Diagnostic Techniques, Neurological; Disease Models, Animal; Dopamine; Fe | 1999 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron | 2001 |
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; D | 2001 |
Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Brain-Derived Neurotrophic Fac | 2001 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain; Cell Count; Disease Models, Animal; Dopamine; Injections, Intrave | 2001 |
Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Cell Division; Cell Survival; C | 2001 |
Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval.
Topics: Age Factors; Animals; Brain Tissue Transplantation; Cell Count; Cell Death; Cell Survival; Corpus St | 2001 |
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Topics: Aging; Animals; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Disease Models, Animal; | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopa | 2001 |
Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.
Topics: Animals; Behavior, Animal; Calbindin 2; Calbindins; Cell Count; Cell Size; Disease Models, Animal; D | 2001 |
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Glial Cell Line-Derived Neurotrophic Factor | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chro | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
Topics: Amphetamine; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Do | 2001 |
Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Disease Model | 2001 |
Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions.
Topics: Action Potentials; Animals; Biological Clocks; Cerebral Cortex; Corpus Striatum; Electric Stimulatio | 2001 |
In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
Topics: Action Potentials; Anesthesia; Animals; Apomorphine; Chloral Hydrate; Corpus Striatum; Disease Model | 2001 |
Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Cell Differentiation; Cell Movement; Cell Survival; Cells, Cultured; Clon | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Do | 2001 |
Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine | 2001 |
Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.
Topics: Adrenal Medulla; Animals; Cell Transplantation; Chromaffin Cells; Corpus Striatum; Disease Models, A | 2001 |
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.
Topics: Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein | 2001 |
Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.
Topics: Adrenergic Agents; Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Male; Models, | 2001 |
Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-R | 2002 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cattle; Nerve Tissue Proteins; Nitric Oxide; Oxidation-Reduction; Oxidopam | 2002 |
Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty.
Topics: Animals; Apomorphine; Behavior, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Male | 2002 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Anima | 2002 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, | 2002 |
Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Topics: Amphetamines; Animals; Astrocytes; Behavior, Animal; beta-Galactosidase; Cells, Cultured; Corpus Str | 2002 |
[Effects of yanggan xifeng recipe on changes of neurological behavior of rat of Parkinson's model].
Topics: Animals; Behavior, Animal; Drugs, Chinese Herbal; Male; Oxidopamine; Parkinson Disease, Secondary; R | 2000 |
Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra.
Topics: Actins; Animals; Antibody Specificity; Apoptosis; Caspases; Cell Compartmentation; Cell Nucleus; Cyt | 2002 |
The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease.
Topics: Amphetamines; Animals; Antigens, Differentiation; Axons; Behavior, Animal; Brain Tissue Transplantat | 2002 |
Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Drug Administration S | 2002 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamin | 1992 |
Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Cryopreservation; Female; Fetal | 1992 |
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1992 |
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat.
Topics: Animals; Benzazepines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Mot | 1992 |
Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dizocilpine Ma | 1992 |
The properties of cultured fetal human and rat brain tissue and its use as grafts for the relief of the parkinsonian syndrome.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cells, Cultured; Cerebral Cortex; Corpus St | 1992 |
Basic fibroblast growth factor ameliorates rotational behavior of substantia nigral-transplanted rats with lesions of the dopaminergic nigrostriatal neurons.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Fibroblast | 1992 |
The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Biomarkers; Corpus Striatum; Immunohistochemistr | 1992 |
MRI, brain iron and experimental Parkinson's disease.
Topics: Animals; Brain; Brain Chemistry; Disease Models, Animal; Estrus; Female; Iron; Magnetic Resonance Im | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; | 1992 |
Implantation of genetically modified mesencephalic fetal cells into the rat striatum.
Topics: Amphetamine; Animals; Autoradiography; Brain Tissue Transplantation; Cell Line; Corpus Striatum; Fem | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
Lesioning of the striatum reverses motor asymmetry in the 6-hydroxydopamine rodent model of parkinsonism.
Topics: Adrenal Medulla; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Graft Survival; Immu | 1991 |
Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Neural Pathways; Oxidopamine | 1991 |
Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease.
Topics: Animals; Apomorphine; Dialysis; Disease Models, Animal; Dopamine; Ganglia, Sympathetic; Hydroxydopam | 1990 |
Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Eating; Feeding and Eating | 1991 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1991 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
[Effect of 6-hydroxydopamine on cerebral catecholamines, lipid peroxidation and antioxidant enzymes in rats-concerned with pathogenesis of Parkinson's disease].
Topics: Animals; Brain; Catalase; Dopamine; Lipid Peroxides; Male; Norepinephrine; Oxidopamine; Parkinson Di | 1991 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleat | 1990 |
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.
Topics: Animals; Benzazepines; Corpus Striatum; Hydroxydopamines; Male; Neurotoxins; Oxidopamine; Parkinson | 1990 |
Effects of transplantation of cross-species substantia nigra into the lateral ventricle of rats with experimentally induced hemiparkinsonism.
Topics: Animals; Apomorphine; Cerebral Ventricles; Graft Survival; Hydroxydopamines; Motor Activity; Nerve R | 1990 |
Adrenal medullary graft to brain in 6-hydroxydopamine-lesioned rotation rats. Comparison of two different graft sites (striatum versus lateral ventricle) by behavioral observation and fluorescence histochemistry.
Topics: Adrenal Medulla; Animals; Cerebral Ventricles; Corpus Striatum; Graft Survival; Hydroxydopamines; Ma | 1990 |
An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats.
Topics: Acrylic Resins; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug | 1989 |
[Results of cross-species transplantation of substantia nigra to the lateral ventricle of the brain of rats with experimentally-induced Parkinson disease].
Topics: Animals; Cerebral Ventricles; Disease Models, Animal; Graft Survival; Hydroxydopamines; Mice; Oxidop | 1989 |
A 6-hydroxydopamine-induced selective parkinsonian rat model.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Disease Models, Animal; Functional Laterality; H | 1989 |
Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation.
Topics: Animals; Corpus Striatum; Dopamine; Fetus; Gestational Age; Humans; Hydroxydopamines; Oxidopamine; P | 1986 |
Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons.
Topics: Amphetamine; Animals; Behavior, Animal; Catecholamines; Cells, Cultured; Corpus Striatum; Disease Mo | 1986 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; L | 1987 |
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Culture Techniques; Dopamine; Humans; | 1987 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D | 1986 |
N-methyl-4-phenylpyridine (MMP+) together with 6-hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calcium; Carbony | 1986 |
Striatal dopamine depletion, dopamine receptor stimulation, and GABA metabolism: implications for the therapy of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hydroxydopamin | 1986 |
A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.
Topics: Animals; Apomorphine; Conditioning, Classical; Corpus Striatum; Dopamine; Hydroxydopamines; Male; Ox | 1986 |
Conditioning of the early behavioral response to apomorphine in the rotational model of Parkinson's disease.
Topics: Animals; Apomorphine; Conditioning, Psychological; Disease Models, Animal; Hydroxydopamines; Male; M | 1988 |
Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Cerebral Cor | 1988 |
Receptor adaptive responsiveness in disease models: 6-OHDA lesioned and spontaneously hypertensive rats.
Topics: Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Hydroxydopamines; Hypertension; Male; No | 1988 |
Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats.
Topics: Adrenal Medulla; Age Factors; Animals; Apomorphine; Hydroxydopamines; Injections, Intraventricular; | 1988 |
Paraneuronal grafts in unilateral 6-hydroxydopamine-lesioned rats: morphological aspects of adrenal chromaffin and carotid body glomus cell implants.
Topics: Adrenal Glands; Animals; Carotid Body; Chromaffin System; Hydroxydopamines; Male; Neurons; Oxidopami | 1988 |
Neurochemical correlates of behavioral changes following intraventricular adrenal medulla grafts: intraventricular microdialysis in freely moving rats.
Topics: Adrenal Medulla; Animals; Behavior, Animal; Cerebral Ventricles; Cerebrospinal Fluid; Female; Hydrox | 1988 |
Cyclosporin A increases survival of cross-species intrastriatal grafts of embryonic dopamine-containing neurons.
Topics: Animals; Cyclosporins; Dopamine; Female; Graft Survival; Hydroxydopamines; Mesencephalon; Mice; Mice | 1985 |
Effects of intracerebral transplantation of immature substantia nigra in rats with experimentally induced Parkinson's disease. II. Results of histopathological and histofluorescent studies.
Topics: Animals; Animals, Newborn; Corpus Striatum; Fluorescence; Follow-Up Studies; Graft Survival; Hydroxy | 1985 |
Stress-induced neurological impairments in an animal model of parkinsonism.
Topics: Animals; Bupropion; Corpus Striatum; Deoxyglucose; Desipramine; Dopamine; Dose-Response Relationship | 1985 |